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CHAPTER 1 
Background and Introduction 
1.1 Addiction 
 The National Institute on Drug Abuse (NIDA) defines addiction as a chronic, relapsing brain 
disease that is characterized by compulsive drug seeking and use, despite harmful consequences [1]. 
NIDA defines physical dependence as the development of neuronal adaptations to repeated drug 
exposure with normal function occurring only in the presence of the drug [1]. When the drug is 
withdrawn, several physiologic side effects can occur, such as seizures, when alcoholics abruptly stop 
drinking [2, 3]. While addiction and dependence are defined separately and are likely mediated in part 
by different brain regions, they are also connected with one another in that dependence often leads to 
addiction. In 2010, an estimated 9% of the population had a substance abuse or dependence problem 
[4]. The ability of drugs of abuse to change a person’s brain and essentially rewire it to require or want 
those abused substances, make it almost impossible for an addict to stop without therapeutic 
intervention [5]. Any individual that tries a drug, legal or illegal, could become addicted, thus it is 
important to understand how various substances of abuse cause alterations to the brain [1, 2]. The only 
way to ensure that an individual does not become addicted is if he or she never takes any type of drug, 
including prescribed pain medication for serious injuries. As that is an unlikely scenario, it is important to 
continue the efforts to understand the complex problem that is addiction. 
 Alcohol in particular is a substance of interest due to its widespread availability and because it 
has been shown to be one of the first substances abused in adolescence [1]. In 2012, 88% of people age 
18 and older have consumed alcohol in their lifetime [6]. Any of those people have the potential to 
become addicted, which could have a number of deleterious effects on their lives and those around 
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them, including untimely death. In the United States approximately 18 million people are affected by 
alcohol abuse or alcohol dependence annually, referred to collectively as alcohol use disorders (AUDs) 
by the National Institute on Alcohol Abuse and Alcoholism [7]. Despite the belief that addiction is an 
individual’s problem, AUDs have high societal costs, from the cost of treatment due to health challenges 
and increased death rates; these issues are further support for the continued study of these disorders 
for successful rehabilitation [7]. To better understand what environmental and genetic factors lead to 
the development of AUDs, extensive research has focused on identifying risk factors predisposing one to 
AUDs. Continued efforts are needed to understand how to best treat individuals with different genetic 
backgrounds and predispositions that make them more susceptible to a loss of control over alcohol.  
1.2 Fundamentals of Neuroscience and Dopamine Neurotransmission 
The brain is a complex network of billions of neurons and neuromodulators working together and 
communicating in elaborate circuitries to maintain normal biological function. The different regions of 
the brain are made up of subsets of specialized neurons that serve different functions; for example the 
region of the amygdala is important in emotion and another region the cortex is responsible for 
initiation of movement [8]. Neurons communicate with one another via intercellular signaling using a 
variety of small chemical messengers called neurotransmitters (Table 1.1). One neurotransmitter of 
importance, which is targeted in some way by all substances of abuse, is dopamine (DA) [5]. DA, a 
catecholamine, is in the monoamine family of neurotransmitters and is synthesized in the neuron from 
the amino acid L-tyrosine (Figure 1.1). DA is involved in a vast array of physiological functions, including 
motor coordination, learning, memory, and drug reward [8].  
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Table 1.1 Common neurotransmitters organized by classification. This table is not 
comprehensive but provides an appreciation for the complexity of communication occurring in 
the brain between different neuron sub-types [8, 9].  
Neurotransmitter Type Neurotransmitters Included 
Individual Neurotransmitters Acetylcholine, Histamine 
Biogenic Amines Dopamine, Epinephrine, Norepinephrine, and 
Serotonin 
Amino Acids Glutamate and γ-amino butyric acid (GABA) 
Purinergic Adenosine triphosphate and Adenosine 
Peptides Families: Opioid, Hormones, Tachykinins, 
Neurotensin, Orexins, Neuropeptide Y, 
Calcitonins, and VIP-Glucagon 
Soluble Gases Nitric oxide, Carbon Monoxide, and Hydrogen 
Sulfide 
 
 
Figure 1.1 Synthesis of DA from L-tyrosine. Step one is hydroxylation of tyrosine by tyrosine 
hydroxylase to produce the intermediate L-DOPA. This reaction is the rate-limiting step. 
Subsequent decarboxylation of L-DOPA then yields DA. 
 
1.2.1 Brain Regions 
There are three important pathways for DA neurotransmission, the nigrostriatal pathway, 
the mesolimbic pathway, and the mesocortical limbic pathway (Figure 1.2, [8, 10]). The 
nigrostriatal pathway consists of DA neurons that project from the substantia nigra (SN), located 
in the midbrain, to the dorsal striatum or caudate-putamen (CPu) in the forebrain. The 
mesolimbic pathway refers to midbrain neurons from the ventral tegmental area (VTA) that 
project to the ventral striatum or nucleus accumbens (NAc). Neurons that originate in the VTA 
and project to the cortex make up the mesocortical pathway. The CPu (dorsal) and NAc 
(ventral), which together comprise the striatum, each serve slightly different physiological 
functions. The CPu can be further divided into two regions: the dorsolateral striatum (DLS) and 
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the dorsomedial striatum (DMS) [11]. Growing bodies of evidence suggest that each of these 3 
regions (DMS, DLS, NAc) have their own specific function in the role of alcohol use and 
dependence [3, 11, 12]. The DLS is implicated in habitual use, while the DMS is involved in 
controlling goal-directed behavior, and the NAc is important in environmental control of 
consumption and relapse [11]. The DLS and DMS are typically grouped together as the CPu in 
rodent models, however in larger mammals as well as in humans the two subsections can be 
more easily distinguished by their medial/lateral position from midline. The NAc is involved in 
memory and motivational processes and has been established as the drug reward center of the 
brain [8]. Research involving drugs of abuse often focuses on the NAc [3, 8, 13], while the CPu in 
the past has had more attention with regard to neurodegenerative disorders such as Parkinson’s 
disease, due to its involvement in motor coordination [12, 14]. More recently, the CPu has been 
gaining attention in later stages of addiction, when drug use is more compulsive and drug 
seeking has more of a habitual pathology [3, 15, 16]. Initially, drug seeking is likely mediated by 
the NAc and the motivation for a pleasurable effect, however over time substance abuse leads 
to neuroadaptations which can lead to habitual behavior mediated by the CPu [3, 12]. The roles 
of both the NAc and CPu are important and therefore efforts should continue to understand 
both as a means to determine the mechanism neuroadaptations associated with long term drug 
use and abuse.   
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Figure 1.2 Representation of the major DA pathways from a sagittal view of a rodent brain, 
inspired from ([8, 10]). 
 
1.2.2 Neuronal Communication 
Most neurons communicate with each other by forming very close connections known as 
synapses in which various extracellular proteins join two neurons [8]. Neurons are made up of 4 
main components: the dendrites, which receive information, the soma (cell body), a single axon 
which propagates processed information from the soma and finally nerve terminals (Figure 1.3). 
The axon of a pre-synaptic neuron creates a synapse with the dendrites of the post-synaptic 
neuron. Intercellular communication between neurons is accomplished by the release of 
neurotransmitters such as DA into the synaptic cleft, which is the small gap between synapsed 
neurons (Figure 1.4). After DA is synthesized, it is packaged into vesicles by vesicular 
monoamine transporters (VMATs, Figure 1.4, [8]). Following stimulation, neurons depolarize 
causing Ca2+ influx through voltage-sensitive Ca2+ channels, which stimulates release of DA 
through exocytosis during which the vesicles fuse to the membrane to release the stored 
neurotransmitter [8]. Released DA in the extracellular space can be taken back into the neuron 
by the DA transporter (DAT), to be recycled, or it can undergo catabolism to generate several 
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metabolites such as homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC). The 
primary action of DA is to act on DA receptors found on the postsynaptic and/or presynaptic 
neuron. DA elicits its effects through activation of one of five receptor sub-types, the D1-Like 
(D1, D5) and D2-Like (D2, D3, D4) receptors [8]. The D1 and D2-like receptors are G-protein 
coupled receptors (GPCRs) that are differentiated based on the type of G-protein they activate: 
D1-like are associated with Gs and D2-like are associated with Gi/Go [8]. The activation of the D1- 
or D2-like receptors regulate cyclic adenosine monophosphate (cAMP) production by 
stimulating or inhibiting adenylyl cyclase (AC), respectively (cAMP signaling is discussed in more 
detail in section 1.2.4 [10]). Two of the D2-like receptors, D2 and D3, are also located on the pre-
synaptic DA neuron, where they function as auto-receptors to regulate DA synthesis and DA 
release [10].   
 
Figure 1.3 Schematic of the four major components of projection-type neurons such as DA 
neurons (inspired from [8]). 
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Figure 1.4 Depiction of a DA synapse showing the nerve terminal of the pre-synaptic neuron and 
the dendrite of the post-synaptic neuron. The space between the two neurons is the synaptic 
cleft, which is about 20 nm in size [17]. Also represented is the release of DA through fusion of 
the vesicle (blue) with the neuron membrane (orange). After release DA transmission occurs 
through interaction with D1- and D2-like receptors. Adenylyl cyclase (AC) is a target of D1-like 
and D2-like receptor activation with the D1- being stimulatory and the D2- being inhibitory. The 
DA transporter (DAT) shown on the nerve terminal is important in recycling and regulation of 
extracellular DA concentrations. The vesicular monoamine transporter (VMAT), responsible for 
the packaging of DA, is highlighted on the DA vesicles. Finally, the protein brain-derived 
neurotrophic factor (BDNF) is also depicted, as well as its receptor tyrosine kinase B (TrkB). 
(Modeled from [8]). 
 
1.2.3 Amino Acid Neurotransmitters 
The amino acid neurotransmitters γ-amino butyric acid (GABA) and glutamate are also 
involved in the nigrostriatal and mesolimbic DA pathways. Typically glutamate and GABA are 
respectively referred to as the excitatory and inhibitory amino acids. There are several 
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glutamate receptor subtypes; two of relevance here are N-methyl-D-aspartate (NMDA) and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA, [8]). The GABA receptors are 
divided into two main groups, the GABAA and GABAB families [8]. The glutamate and GABA 
amino acid neurotransmitters are important because they converge, are connected with, and 
regulate DA neurotransmission. About 95% of the neurons in the striatum (NAc and CPu) are 
GABAergic medium-sized spiny projection neurons [13], which receive input from glutamate 
neurons of the cortex and DA neurons of the midbrain (Figure 1.5). Figure 1.5 shows an updated 
representation of the DA pathways, this time including the connections of the amino acid 
neurotransmitters in these particular brain regions. Together these neurotransmitters have a 
mutual relationship in their ability to modulate the neurotransmission of one another. Although 
the consideration of only DA makes experimental interpretation in relation to alcohol 
dependence simpler, the other neurotransmitters need to be considered as well. The amino acid 
receptors NMDA and GABAA are both targets of ethanol [10], which complicates the 
understanding of whether DA observations are primary or secondary effects of ethanol. 
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Figure 1.5 A simplified representation of the innervation of DA from the midbrain to the 
striatum and cortex. There is also mixed innervation from the amino acid neurotransmitters 
glutamate (excitatory) and GABA (inhibitory) in these three regions [18, 19]. 
 
1.2.4 Intracellular Signaling 
In addition to the intercellular signaling that occurs across complex networks of 
neurotransmitters, there is also a vast amount of intracellular signaling taking place in these 
neuronal sub-populations. There are several small molecule, peptide, and protein 
neuromodulators that can alter the communication between different types of neurons.  Two of 
those relevant for this dissertation are cAMP and brain-derived neurotrophic factor (BDNF).  
 cAMP is an important second messenger with its signaling being involved in learning and 
memory; as such it is also of interest with regard to drugs of abuse and addiction [10, 20]. 
Adenosine triphosphate is converted to cAMP through the action of ACs [10]. There are 10 
mammalian AC isoforms that have variable distributions in different brain regions and neuron 
types, allowing cAMP-signaling to serve multiple distinct functions [10]. Increases in cAMP 
promote dissociation of protein kinase A (PKA) regulatory subunits from the catalytic subunits 
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leading to further phosphorylation of downstream targets, one of which is the cAMP response 
element binding (CREB) protein [10]. Activation of CREB stimulates gene transcription, which 
produces various physiological outputs, such as enhanced neuroplasticity through increased 
expression of structural proteins [8]. The role of CREB in learning is still under investigation in 
mammalian models but in Drosophila, CREB mutants showed deficits in learning and memory [8, 
10].  
BDNF is a 14 kDa protein in the neurotrophin family important for neuronal survival, 
differentiation, and plasticity [21]. BDNF binds as a dimer to its receptor, tyrosine kinase B 
(TrkB), causing internalization and auto-phosphorylation (Figure 1.6, [20]). Several signaling 
cascades are then activated through recruitment of adapter proteins, such as mitogen-activated 
protein kinase (MAPK), phosphatidylinositol-3-OH kinase (PI3K), and phospholipase Cγ (PLCγ) 
(Figure 1.6, [21]). One outcome of activation of these pathways is enhancement of CREB 
regulated gene transcription, yielding diverse biological outcomes such as enhanced synaptic 
plasticity (the strengthening of synapses). Furthermore, BDNF itself is a target of CREB and its 
transcription is regulated by it [20]. In addition to the trophic function of BDNF it, like cAMP, is 
important in learning and memory and, as such, is of interest in substance abuse studies.  
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Figure 1.6 Schematic of BDNF-signaling initiated by binding with its receptor TrkB and 
subsequent activation of kinase signaling cascades to regulate the CREB transcription factor. 
Also depicted is the CREB regulation of BDNF transcription. 
 
1.3 BDNF and Ethanol 
 There is a body of evidence suggesting the comorbidity of psychiatric disorders in 
people suffering from alcohol dependence, which makes understanding the motivation for 
alcohol consumption all the more complicated [21, 22]. In a clinical study by Goldstein et al., a 
variety of disorders such as anxiety, depression, and schizophrenia were shown to pre-dispose 
patients to ethanol abuse [22]. BDNF is a common factor that has been implicated in psychiatric 
disorders and addiction and has been investigated in an effort to elucidate its role in both [21]. 
In humans, mutations in the BDNF gene have been linked to increased vulnerability and relapse 
to alcoholism [21, 23, 24]. A region on chromosome 11, which contains the BDNF gene, has been 
associated with increased vulnerability to polysubstance abuse, including alcohol, in humans 
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[23]. Polymorphisms in the BDNF gene have also been associated with an earlier onset of 
alcohol abuse and a faster rate of relapse in alcoholics [24]. Additionally, decreased plasma 
BDNF levels have been observed clinically in alcoholics [25]. In rodent models, BDNF-deficient 
mice consumed more alcohol than control mice and pharmacologic manipulations in control 
animals that reduced BDNF levels also led to increased consumption; together evidencing a role 
for BDNF to influence alcohol consumption and preference [26-28]. Further studies to 
determine the relationship between BDNF and ethanol have also revealed the ability of ethanol 
to alter BDNF protein and mRNA expression [20, 21, 26, 29]. In mouse models, acute 
administration of ethanol reduced BDNF protein levels in the striatum [29] and increased BDNF 
mRNA levels [26]. The mRNA levels of the TrkB receptor of BDNF are also altered following 
exposure to ethanol [21, 30]. Taken together, it is clear that BDNF plays a role in alcohol 
consumption and dependence. Conflicting reports of ethanol’s effect on BDNF expression [26, 
29], together with the reciprocal relationship of BDNF and ethanol, merit further investigations 
to understand the exact roles of BDNF and the mechanisms through which it carries out its 
function.   
1.4 Dopamine, Ethanol, and BDNF 
Thus far evidence has been given for BDNF’s role in alcohol consumption and 
dependence, as well as the importance of the neurotransmitter DA in substance abuse. BDNF 
alters DA transmission through direct stimulation of DA release and by reduced DA release in 
BDNF-deficient mice, which can be rescued by BDNF perfusion [31-33]. Ethanol increases DA in 
both regions of the mouse striatum following intraperitoneal (i.p.) administration [5, 29, 34, 35]. 
Previous studies, using BDNF-deficient mice, have shown that ethanol stimulated DA release is 
blunted in the deficient mice compared to wild-type (WT) mice [29]. Further evidence for the 
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importance of DA in ethanol consumption and dependence is found in alcoholic patients who 
have less DA D2 receptors compared to non-alcoholic patients, which could either be a factor 
for predisposition to alcoholism or a result of repeated ethanol exposure [36-38]. Investigations 
of the D2 receptor after ethanol exposure have shown variable results in D2 function or 
localization depending on the type of assay, method of ethanol exposure, and animal model 
[39]. The D2 receptor appears to regulate ethanol consumption, as shown in D2 receptor knock-
out mice that are devoid of the long-form of the receptor [40]. The knockout of long form D2 
receptor causes up-regulation of the short form D2 receptor and these animals consume more 
ethanol than control mice [40]. Again, BDNF could be an important factor mediating not only the 
release of DA in the presence of ethanol but also alterations in the D2 receptor.  
1.5 Dissertation Specific Aim 
The interactions of BDNF, DA, and ethanol in the brain are incredibly complex given the 
reciprocal relationships of these molecules and the other neuronal systems implicated with 
ethanol use and exposure. The purpose of this study was to determine the effect of ethanol on 
the CPu in the presence of low endogenous BDNF levels to gain a better understanding of how a 
mutation in an individual’s BDNF gene may promote their loss of control over alcohol use. This 
goal was achieved using genetically altered mice that have a 50% reduction in BDNF protein and 
mRNA levels (BDNF+/-, BDNF heterozygous) and achieving ethanol exposure through the use of a 
voluntary ethanol consumption protocol, drinking in the dark (DID). After 7 days of exposure, DA 
neurotransmission, as well as BDNF-signaling, was assessed in the striatum of WT and BDNF+/- 
mice. The findings presented herein show significant striatal alterations after just 7 days of 
ethanol exposure and provide important and new information regarding this DID model.   
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CHAPTER 2 
Methods and Methodological Considerations 
This chapter provides a detailed description of methods used for the experiments throughout 
this dissertation, as well as some background discussion on select techniques.  
2.1 Animals  
 Wild-type (WT, strain: C57BL/6J) and brain derived neurotrophic factor (BDNF) deficient 
mice (BDNF+/-, strain: B6.129S4-Bdnftm1Jae/J) were originally purchased from The Jackson 
Laboratory (Bar Harbor, ME) at the age of 3-5 weeks. BDNF+/- mice have a normal appearance 
and behavior despite a 50 % reduction in both mRNA and protein levels of BDNF. BDNF-/- mice 
which are complete knockout animals and are not used because they are not viable past 21 
days. Upon acclimation (2 weeks), male BDNF+/- mice were placed with 1-2 C57BL/6J female 
mice for breeding. At 21 days of age, offspring were marked using an ear punch and tail biopsies 
were collected for PCR determination of genotype. Animals were housed in groups of 4-6, 
separated by gender, on a 12-hour light/dark cycle (0600 lights on). Cages were outfitted with 
corn cob bedding and Nestlets™ for environmental enrichment with food and water available ad 
libitum. Mice were used at about 4-6 months of age, and were moved to a different room for 
drinking studies carried out on a reverse light/dark cycle. All procedures were designed and 
conducted to minimize pain and discomfort to the animals. Animal care and use was in 
accordance with the National Institutes of Health Animal Care guidelines and approved by the 
Wayne State University Institutional Animal Care and Use Committee. 
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2.2 Genotyping 
Tail biopsies were processed into smaller pieces using a razor blade to chop the tail into 
6-8 individual pieces. The pieces were incubated overnight in a water bath at 55 ○C in a lysis 
buffer containing: 0.1 M Tris base, 5 mM ethylenediaminetetraacetic acid (EDTA), 0.2% sodium-
dodecyl sulfate (SDS), 0.2 M NaCl and 0.1 mg/mL proteinase K (New England BioLabs, Ipswich, 
MA). After 15-24 hours samples were vortexed and centrifuged (16 minutes, 20,000 RCF). The 
supernatants were transferred to a second set of tubes containing 500 µL of isopropyl alcohol 
each. These tubes were mixed by inversion, and centrifuged (16 minutes, 20,000 relative 
centrifugal force (RCF)). The supernatants were removed and 500 µL of 75% (v/v) ethanol was 
added to each pellet. Again the tubes were mixed by inversion and centrifuged (5 minutes, 
20,000 RCF). The supernatants were removed and 6 µL of water was added, after which the 
tubes were placed in a vacuum desiccator to remove ethanol. The pellets were reconstituted in 
85 µL of TE buffer (10 mM Tris base and 1 mM EDTA, pH 8.5) and stored at 4 ○C until polymerase 
chain reaction (PCR) amplification was carried out.  
 Each mouse had two PCR reactions using its DNA, one for the WT primer and one for the 
BDNF+/- primer. Initially, the PCR procedure required making our own master mix containing: 
1.28 mM MgCl2, 0.48X PCR Buffer A (10 mM Tris-HCl, 1.5 mM MgCl2, 50 mM KCl; pH 9.0), 0.096 
mM dNTPs, and 1 µM control (or common) primer (ATGAAAGAAGTAAACGTCCAC). This master 
mix, 1 unit Taq DNA Polymerase and either 1 µM BDNF+/- (GGGAACTTCCTGACTAGGGG) or WT 
primer (CCAGCAGAAAGAGTAGAGGAG) was added to 4 µL of a DNA sample. Primers were 
purchased from Invitrogen (Grand Island, NY) and were designed based on The Jackson 
Laboratories (Bar Harbor, ME) recommendation for this mouse strain. The PCR reaction was 
performed using a thermocycler (Robocycler® gradient 96, Stratagene/Agilent, Santa Clara, CA). 
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The conditions were 94 ○C for 2 minutes, followed by 35 cycles of 94 ○C, 55 ○C, and 72 ○C for 30 
seconds each, and a final 2 minute cycle at 72 ○C. This method was useful but inconsistent 
because it often required troubleshooting in an effort to pinpoint the reagent that was causing 
problems. Additionally, this approach involved the addition of very small quantities of Taq 
Polymerase, which likely contributed to the poor dependability of the reaction due to 
inaccuracies in pipetting.  
In an effort to improve the throughput of genotype analysis, a commercially available 
master mix, GoTaq® Hot Start Green Master Mix, from Promega (Madison, WI) was tested. The 
only additions required to this mix were DNA, water, and primers. This approach proved to be a 
much simpler reaction preparation and thus far has been more robust for continued genotypic 
analysis. The same cycling conditions on the thermocycler were used for both reactions. This 
master mix also simplified gel analysis because loading dye was already mixed in, minimizing 
another pipetting step in our analysis. 
 PCR products were electrophoresed on a 2% agarose gel containing 0.02% ethidium 
bromide in 1X TBE buffer (2.5 mM NaOH, 89.2 mM Tris Base, 89.0 mM boric acid, and 2.5 mM 
EDTA). The gel was prepped by heating the agarose and TBE buffer mixture (above) in the 
microwave until agarose was fully dissolved. After a brief cooling period ethidium bromide was 
added and the gel was poured into a rig with the comb in place. Once cooled the gel was placed 
in the running rig which was filled with the 1X TBE running buffer. 6 µL of sample were loaded 
on the gel with the WT reaction first, followed by the mutant reaction (Figure 2.1). The gel was 
electrophoresed at 125-135 V for about 45 minutes and imaged on a Typhoon 9210 scanner 
(Amersham Biosciences, Pittsburg, PA) at a fluorescence of 500 nm. WT mice were those with 
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only one DNA product; BDNF+/- mice also contained a second larger band from the PCR reaction 
using the mutant primer (Figure 2.1). 
Figure 2.1 Representative agarose gel image used for the determination of mouse genotypes as 
WT or BDNF+/-. The numbers across two lanes refer to the animal number that is defined during 
weaning when the tail biopsies are collected. The (+/-) notation indicates a BDNF+/- mouse given 
that there is a 250 bp band in the first (WT) lane for that mouse and a ~300 bp band in the 
second (BDNF+/- or mutant) lane. The (+/+) means the animal is a WT because no reaction 
occurred with the BDNF+/- primer.  
 
2.3 Ethanol Consumption 
2.3.1 Drinking Models 
 Mouse models are often used in neuroscience research because of the speed of 
reproduction, minimal expense, and ease of genetic modification, compared to other models 
[11]. When using animal models to represent human problems, the route and frequency of 
exposure is an important consideration. Routes of ethanol exposure include involuntary 
exposure through injection or vapor chamber or voluntary consumption through different 
drinking models. Some research has shown evidence that the involuntary routes of exposure do 
not activate the same neuronal pathways, such as those for habit-formation, in the same way as 
voluntary consumption protocols [41]. A subsequent challenge using voluntary consumption 
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models is replicating the human condition, which varies not only with age but also by the stage 
of addiction [42]. Heavy or excessive alcohol consumption is considered an important 
characteristic of alcohol dependence and addiction, as such this is a desirable feature of a 
drinking model [42]. A commonly used model of voluntary ethanol consumption is referred to as 
the 2-bottle choice assay in which animals have access to water and a solution of ethanol for 24 
hours. The two-bottle choice assay allows for assessment of preference because animals have a 
choice. One drawback is that, due to the extended period of exposure, it is unclear if 
pharmacologically relevant blood alcohol levels are reached [42]. A recently developed model 
known as drinking in the dark (DID) promotes excessive ‘binge’-like consumption to produce 
pharmacologically relevant blood alcohol levels (80.0 mg/dL) [43]. The DID protocol requires 
reversing the mouse’s light/dark cycle and giving it limited access to only ethanol for 2-4 hours, 
starting 3 hours into the dark cycle, which resulted in higher consumption compared to starting 
at 1 or 2 hours into the dark cycle [43]. Ethanol consumption using the DID model was unaltered 
by varying the ethanol concentration and remained stable for up to 14 days [43]. The use of the 
C57BL/6J strain of mice was also important in achieving these high levels of consumption, as 
assessed in the study by Rhodes et al. [44]. ‘Binge’-like consumption has been given far less 
attention in studies of addiction despite the fact that it may be an important factor in the 
development of dependence, and as such, it should be investigated along with acute and 
chronic models of ethanol exposure [45, 46]. Information and considerations for the DID model 
have been reviewed previously (see [47]) and findings thus far from its use in rodent models 
have also been reviewed recently (see [46]). 
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2.3.2 Drinking in the Dark Protocol 
  The overall goal of this work was to assess the effects of ethanol on the striatum in a 
mouse model with low endogenous BDNF levels by using the voluntary ethanol consumption 
DID model for 7 days. Animals were acclimated to a reverse light/dark cycle (0600 lights off) for 
a minimum of 2 weeks before drinking exposure. Animals were also habituated to the single-
housed conditions required for the procedure for about 1 week before DID started. On ethanol 
drinking days, 3 hours into the dark cycle the home cage water bottle was removed and 
replaced with a pre-weighed bottle containing a 15 % ethanol (v/v) solution in tap water. Mice 
were left undisturbed with ethanol bottles for two hours. At the end of the DID session, the 
bottles were removed and weighed. The grams of ethanol consumed were calculated and 
normalized to the kilograms of mouse weight (reported as ethanol intake g/kg). On the seventh 
day of DID, animals either underwent surgery, were sacrificed for tissue, or remained in the 
animal room for 24 hours and then sacrificed for tissue. The mice that underwent surgery on the 
last day of DID were used for neurochemical characterization by microdialysis the following day, 
24 hours after the last drinking session.  
2.4 Microdialysis 
2.4.1 Techniques for In Vivo Neurotransmitter Analysis 
 Monitoring neurotransmitters in humans poses a unique challenge as the brain is not 
easily accessible for measurements from an alive and intact system. The immense cross-talk 
between different neuron types and brain regions require an intact system to properly 
understand human conditions. For example the amino acid neurotransmitters that are targeted 
by ethanol and also regulate DA neurotransmission, these systems project across several brain 
regions and act in concert with each other highlighting the importance of an intact system. 
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Scientific advancements have provided solutions to these challenges with tools to measure 
neurotransmitter function in both human and animal models. These techniques include imaging 
with contrast agents, biosensors, microelectrodes, and in vivo sampling techniques [9, 48].  
 In humans and animals, positron emission tomography (PET) or magnetic-resonance 
imaging (MRI or functional MRI) can be used to determine receptor activity or general brain size 
and function [48]. For example, in a study by Childress et al., detoxified cocaine users were 
compared to cocaine naïve individuals. Their cerebral blood flow was measured using PET 
imaging while watching a cocaine video [49]. The cocaine users experienced increased blood 
flow in some regions and decreased flow in other regions; these changes were not observed in 
the cocaine naïve individuals [49]. This experiment demonstrates how valuable these techniques 
can be for understanding brain function; however they do not always provide the required 
spatial or temporal resolution to understand dynamic processes in the brain.  
Many neuroscience methods rely heavily on animal models for multiple reasons, 
including the relative cost and tendency for breeding; mice specifically are desirable for the ease 
with which they can be manipulated genetically. In animal models, advancements in 
neurotransmitter analysis have come in the form of biosensors, microelectrodes, sampling 
techniques and separation methods. Microelectrodes and biosensors can be used directly in the 
brain provided they are designed to be selective for the analyte of interest and maintain proper 
function in the brain tissue [9, 48]. Another common method is to use a sampling technique 
such as microdialysis to collect fluid from the extracellular space. In addition to being used 
directly in the brain, biosensors and microelectrodes can also be used with samples collected via 
microdialysis.  
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Microdialysis allows for the collection of a mixture of small molecules from the 
extracellular space from awake and freely moving animals. Microdialysis probes are equipped 
with a semi-permeable membrane with a molecular weight cut-off to exclude larger molecules, 
producing inherently clean samples (Figure 2.2). First, a guide cannula is inserted into the brain, 
which directs the microdialysis probe to a region of interest. Perfusion of the probe with a 
buffer similar to the biological matrix, termed the perfusate, produces a concentration gradient 
around the probe. Small molecules travel down the generated concentration gradient and into 
the probe for collection. Perfusate exiting from the probe is termed dialysate and can be 
processed in several ways. Initially analysis of dialysate is achieved by separation using liquid 
chromatography or capillary electrophoresis to separate the complex mixture. After separation, 
a multitude of detection schemes can be used to quantify the analyte of interest based on its 
chemical properties. Catecholamines such as dopamine (DA) are electroactive and are typically 
quantified via electrochemical detection, whereas non-electroactive neurotransmitters (e.g. 
amino acids) are usually derivatized so that fluorescence or electrochemical detection can be 
used [9, 48]. For this work, the analyte of interest was DA, and high performance liquid 
chromatography (HPLC) with electrochemical detection was used.    
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Figure 2.2. Diagram of an inserted microdialysis probe in the CPu (left) using a stained mouse 
slice. The expansion of a microdialysis probe (on the right) highlights the diffusion of small 
molecules (triangles and circles) into the probe and the exclusion of larger molecular weight 
molecules (squares). 
 
2.4.2 Surgical Details 
 On days of surgery in preparation for microdialysis experiments, animals were moved 
from the colony to the laboratory, which had a separate room dedicated to surgical procedures, 
and allowed to acclimate. Mice were anesthetized using isoflurane inhalation, delivered with 
medical grade O2 (g). Animals were induced in a chamber at 3% isoflurane delivery and 
subsequently transferred to a nose piece and maintained at 1.5-3% isoflurane. The animals were 
maintained in a surgical plane of anesthesia, which was verified by assessing the pedal 
withdrawal reflex. Before the procedure began, animals were injected with 0.2 mL of sterile 
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saline (0.9% NaCl) to aid in recovery from the procedure. In addition, sterile ophthalmic 
ointment was applied to the eyes to retain moisture and mice were placed on an isothermal 
heating pad to maintain body temperature.  
 The top of the head was shaved using a Remington beard and mustache trimmer so that 
the scalp could be cleaned. The incision area was cleaned three times, alternating between 
Betadine and 70% ethanol, followed by subcutaneous injection, in an elliptical pattern, of a local 
analgesic (0.5 mg/kg lidocaine + 1.5 mg/kg bupivacaine). A small circle of skin was then incised. 
A solution of 10% (v/v) hydrogen peroxide was applied to dissolve the perosteum and expose 
the skull to make the markings of bregma more defined. The bregma is the T-shaped 
intersection, which is the result of different skull sections fusing together and is used as an 
anatomical marker to target specific brain regions. Mice were placed on a stereotaxic frame 
(Figure 2.3) to achieve a flat and level skull surface. The guide cannula was positioned over 
bregma to read the associated anterior/posterior (AP) and medial/lateral (ML) coordinates. 
After applying the correction to target for the brain region of interest, a mark was made on the 
skull. Using a drill, a small burr hole was made to fit the guide cannula and, in the opposing 
quadrant, another small hole was made for placement of a bone anchor. The guide cannula was 
placed over the hole and the coordinates were recorded again. This time a dorsal/ventral (DV) 
reading was taken, and, as before, a correction was applied to insert the cannula to the proper 
depth. The guide cannula was secured in position using dental cement and the animal was 
allowed to recover on a heating pad.  
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Figure 2.3. Picture of the stereotaxic frame used for surgeries with a mock animal in place.  
 Once the mice regained consciousness, they were transferred to a cylindrical bucket 
equipped for in vivo microdialysis. Two to four hours after surgery the ‘dummy’ probe was 
removed from the cannula and the CMA/7 2 mm microdialysis probe (0.24 mm diameter, 
Cuprophane, 6 kDa cut-off, Harvard Apparatus Inc) was inserted. Microdialysis lines and probes 
were cleaned offline using the antimicrobial ProClin® (BASi, West Lafayette, IN) and 70% ethanol 
(v/v), followed by perfusion with sterile artificial cerebrospinal fluid (aCSF, composition: 145 mM 
NaCl, 3.5 mM KCl, 2.0 mM Na2HPO4, 1.0 mM CaCl2, 1.2 mM MgCl2, pH = 7). ACSF was 
continuously perfused at a flow rate of 1.1 µL/min overnight and experiments were started the 
next day.  
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During microdialysis sampling, fractions were collected every 20 minutes, providing 
about 21 µL of dialysate for analysis per sample. Most dialysis experiments herein involved 
pharmacologic manipulation of some form. For such experiments, 3 baseline fractions were 
collected providing uncorrected extracellular DA levels, followed by drug treatment and 
subsequent fraction collection. All samples either pre- or post-drug were normalized to the 3 
averaged baseline samples (set to 100%). The baseline correction achieved by normalizing 
values to the averaged baseline allows for individual variability between mice to be accounted 
for. Pharmacological treatment using microdialysis was carried out in several ways including 
systemic injection of the drug or targeted application through retrodialysis (perfused through 
probe) of the drug mixed into the aCSF. Baseline correction of experiments allows for variability 
in baseline DA levels to be accounted for between mice. 
2.4.3 Zero Net Flux 
 As mentioned above, typically extracellular DA levels are determined without assessing 
the recovery of the microdialysis probe. However, there are some instances where determining 
the ‘true’ extracellular DA levels are beneficial to understand. The method of quantitative 
microdialysis also known as no net flux or zero net flux, allows for the determination of ‘true’ 
basal extracellular dopamine levels, which differ from extracellular levels determined directly 
from dialysate because it accounts for the recovery of the microdialysis probe. When 
determining ‘true’ extracellular DA levels it is important to consider that measurements are 
being made from a dynamic system which undergoes constant fluctuations with both passive 
(diffusion away from the synapse)  and active processes (re-uptake and catabolism) occurring 
that can affect the diffusion of the analyte into the probe. Several quantitative approaches to 
determine extracellular DA levels have been assessed, which involve variations in flow rate of 
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the perfusate or varying concentrations of perfused analyte [50]. Microdialysis is possible 
because of the diffusion gradient created at the probe; as such, the recovery rate of analytes is 
dependent on the perfusate flow rate. Lower flow rates yield higher recovery because there is 
more time for equilibration around the probe. The variable perfusion method extrapolates from 
DA levels determined at different flow rates to determine the DA concentration at zero flow, 
which would be when the dialysate is in equilibrium with the extracellular fluid [50]. The 
drawbacks to the variable flow method are that it requires long sampling times and the 
determination of extracellular concentration is based off of interpolation of a non-linear curve 
[50]. The variation in concentration method, described below, is simpler and generates linear 
curves for interpretation and therefore it was used for this study.   
 The variation in concentration method, also called the difference method, is commonly 
referred to as no net flux or zero net flux. Using zero net flux, known concentrations of DA are 
added to the perfusate that bracket the expected extracellular concentrations. A programmable 
perfusion pump equipped with a ‘Y’ connector and two syringes: one with a stock standard of 20 
nM DA and another with only aCSF. The pump was programmed such that concentrations of 0, 
5, 10, and 20 nM DA were also perfused, for 1.5 hours each. Additionally, the concentrations of 
20, 10 and 5 nM were assessed and quantified in an in vitro calibration to account for 
differences in making solutions from experiment to experiment and mixing variations of the 
perfusion pumps. The perfused DA (DAin) minus dialysate DA output (DAout) were plotted (DAin – 
DAout, y-axis) versus DAin (x-axis) providing four data points (0, 5, 10 and 20 nM DA). A linear 
regression was run on these points to get a linear equation, y = mx + b where m is the slope and 
b is the y-intercept. The x-intercept, where there is no loss from the brain or gain to the brain, 
then represents the ‘true’ extracellular concentration of DA (DAext).  
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The zero net flux difference method also provides an additional piece of information 
about the in vivo recovery of the probe, which indicates DA turnover efficiency [50]. According 
to a review by J.B. Justice, there are passive and active processes affecting probe recovery [50]. 
Passive processes include the reduced volume for transport and increased tortuosity 
(complexity of path analytes must traverse) in the tissue as compared to a homogenous solution 
[50]. Active processes to consider include metabolism and reuptake, due to their ability to alter 
concentrations of analytes in the extracellular space being samples from. J.B. Justice assessed 
data from zero net flux experiments of DA and its metabolite DOPAC, as well as a series of 
pharmacologic manipulations targeting release, metabolism, and reuptake processes, it was 
concluded that for neurotransmitters such as DA, the primary component affecting probe 
recovery was DA reuptake by the transporter [50]. As such, the slopes from the linear regression 
lines of the zero net flux data can be used to assess DA transporter function.  
2.5 Histological Verification of Probe Placement 
 Confirming placement of the probe after experimentation is important to verify that 
observations are in fact from the targeted brain region. Compared to the NAc, the CPu probe 
placement is more easily confirmed by sectioning of the brain due to the large size and 
anatomical markers present in the tissue itself.  It is also less likely that the CPu is missed when 
doing a surgery; due to its large size and the probe size, there is more room for deviation from 
the coordinates to target that region. When verifying probe placement in the NAc, additional 
measures were required to visualize the probe and verify correct placement.  
 Initially, placement was verified by euthanizing the mouse using CO2 asphyxiation with 
the probe still inserted into the brain region of interest. Crystal violet stain (~500 µL) was then 
manually pushed through the probe. The brain was removed and sectioned on a vibratome. 
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There were several disadvantages to this verification method, the main one being inconsistency. 
The dye did not always perfuse out of the probe very well, which led to a poor marking of probe 
position. The brain tissue was also very fragile to work with. Depending on the brain, the 
thinnest slices that could be achieved were 400 μm, which is bigger than the probe, meaning the 
necessary slice was not always obtained. Additionally, this method had to be done immediately 
following the experiment otherwise the probe became clogged and dye could not be pushed 
through.  
 A more convenient alternative method was developed in Dr. Matthew Allen’s lab 
(Wayne State University, Chemistry Department), which involved staining the entire brain [51]. 
Their method was optimized for our purposes of histological verification of probe placement. 
The method offered an advantage of experimenter convenience in that it allowed tissue 
collection and storage so that the staining and probe verification could take place at a later time. 
Tissue was fixed in formalin (3.7% v/v) and stored at 4 ○C until ready to use. When ready, tissue 
was rinsed in DI water and the brain was incubated in a solution of cresyl violet (0.2% w/v in an 
acetic acid (0.2%) and ethanol (98%) aqueous mixture) for 23-24 hours at room temperature. 
Tissue differentiation occurred using 70% ethanol (v/v, 20–25 mL) for 24 h, and the 
differentiation fluid was changed once after 3-4 h. After the second differentiation period (20–
21 h), the solution was changed to 95% ethanol and differentiated for 30 min. Finally, the brain 
samples were hydrated in water for 1 h before suspension in agarose gel. Tissue was sliced into 
150 µm thick coronal slices for imaging. The fixed tissue and fixation in agarose before slicing 
provided more durable brain slices and the ability to obtain thinner slices which were ideal for 
capturing the location of the microdialysis probe.  
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 Figure 2.4 shows a comparison of probe placement verification using the probe 
perfusion method compared to the whole tissue staining method. Figure 2.4A is an example of 
the crystal violet perfusion method working well, while Figure 2.4C is an example of one of the 
many ways it could fail. While both techniques allowed for verification, the latter method was 
more reliable and the images are consistently comparable to that of Figure 2.4B. The whole 
brain method also provided enhanced experimenter convenience.  
A 
 
B 
 
C 
 
Figure 2.4 Examples of brain slices from probe placement verification using the crystal violet 
perfusion method and cresyl violet whole brain staining method. A) A successful verification 
with the crystal violet perfusion method where the probe is clearly visualized (purple line). B) 
Representative brain slice for probe placement using the whole brain cresyl violet method; this 
is consistently what would be observed. C) The perfusion method (also in A) was not reliable for 
various reasons and this is an example of what could go wrong, with the dye spilling out and the 
probe location not being determined. 
 
2.6 Microdialysis Sample Analysis 
As previously mentioned, HPLC coupled with electrochemical detection was used to 
quantify DA concentrations from dialysate samples collected by microdialysis. An isocratic 
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Shimadzu LC-20AD HPLC pump delivered mobile phase to a Phenomenex C18 (2)-HST HPLC 
column (100 mm x 3 mm, 2.5 um) at a flow rate of 0.4 mL/min. Mobile phase composition was 
75 mM NaH2PO4 monohydrate, 1.6 mM 1-octanesulfonic acid, 0.025 mM EDTA, 10% 
acetonitrile, and 0.002% triethylamine, with a pH of 3 adjusted with 85% phosphoric acid. 
Samples (20 µL) was injected by overfilling a 20 µL sample loop with the 21 µL dialysate sample 
and detection occurred with an ESA 5014B microdialysis cell (E1 = - 150 mV, E2 = +220 mV). A 
guard cell (ESA 5020) set to a potential of + 350 mV was placed in-line before the injection loop. 
Peak areas were integrated and quantified against known standards using LC Solutions 
Shimadzu Software.  
2.7 Tissue Content Studies  
 For tissue content studies, animals were euthanized using cervical dislocation followed 
by excision of the brain. The brain was free-hand dissected into brain regions of interest using 
anatomical markers visual to the eye and snap frozen in liquid nitrogen. Brain samples were 
stored at -80 ○C until used. Tissue content studies include: determination of BDNF protein levels 
using a commercially available ELISA kit (Promega, Madison, WI), the BDNF receptor tyrosine 
kinase B (TrkB) and its activation by phosphorylation (pTrkB). The latter receptor studies were 
assessed by measuring protein levels using immunoblotting. Detailed methods are provided in 
Chapter 4 
2.8 Data Analysis 
 Plots of data were created solely using GraphPad Prism v5 software. Statistical analysis 
was carried out using GraphPad or, when the appropriate statistical functions were not 
available, Statistical Package for the Social Sciences (SPSS) was used. Most microdialysis 
experiments and drinking data were analyzed using repeated measures analysis of variance 
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(ANOVA). Other data were analyzed using an appropriate ANOVA or t-test. In most cases of 
repeated measures analysis, sphericity was violated due to the pharmacological manipulation in 
these experiments so the Greenhouse-Geisser correction was used. One caveat of the repeated 
measures design is that animals are excluded if they are missing any measures over time 
compared to the rest of the group. When using an in vivo animal model, there are a lot of 
challenges that can be encountered in just collection of the sample, as well as during analysis. As 
such, there are often samples missing (typically 0-2 samples per mouse). For example in an 
animal where 12 samples are collected over the course of 4 hours, if the animal gets 
disconnected for one of the 20 minute samples, the whole animal would be excluded. This 
exclusion then results in the statistical analysis only including around 20% of the subjects. The 
field of psychology often uses the repeated measures design where clinical data is used with 
much larger n values so losing a few is insignificant, therefor there is not a standard resolution 
for missing data in animal models where the groups are much smaller. One possible solution 
would be to increase group sizes, however when using animal models the goal is always to 
reduce numbers and minimize usage. The use of unlimited animals for the purposes of collecting 
complete data sets would be a waste of animal lives and resources. This problem with statistical 
analysis, is well known however, there is no standard solution in the field. One solution, which is 
used here, is mathematical modeling and prediction of the missing time points. One model for 
doing this is the expectation maximization method available in the SPSS software, and from 
experience working with microdialysis, the predictions made using this model are reasonable. As 
such, missing value analysis was performed on microdialysis data and DA concentrations from 
missing time points were predicted for further analysis using the repeated measures ANOVA. 
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2.9 Chemicals 
 Reagent kits and enzymes were from various vendors which were specified in the text 
where they were used. All other chemicals used to make buffers, mobile phase and aCSF were 
purchased from Fisher Scientific (Ottowa, Ontario), EMD (Darmstadt, Germany), or Sigma-
Aldrich (St. Louis, MO) and were of HPLC grade quality. 
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CHAPTER 3 
 
Striatal Dopamine Tolerance to Ethanol Following Seven Days of Drinking 
in the Dark 
 
A similar version of this chapter and the data described within is being submitted to the Journal 
of Neuropharmacology.  
 
3.1 Introduction   
Approximately 18 million people annually in the US are affected by alcohol abuse or 
alcohol dependence, referred to collectively as alcohol use disorders (AUDs) by the National 
Institute on Alcohol Abuse and Alcoholism [7]. To better understand what environmental and 
genetic factors lead to the development of AUDs, research has focused on identifying risk 
factors predisposing one to AUDs. Both clinical and preclinical research has suggested brain-
derived neurotrophic factor (BDNF) as a risk factor. In humans, mutations in the BDNF gene are 
linked to increased vulnerability and relapse to alcoholism [21, 23, 24]. In rodent models, BDNF 
levels influence alcohol consumption and preference [26-28]. BDNF heterozygous (BDNF+/-) 
mice, which have a 50% reduction in BDNF mRNA and protein, consume more alcohol in a two-
bottle choice assay, and show a preference for ethanol in conditioned place preference testing 
[26, 28]. Additionally, administration of a fusion protein containing RACK1, a scaffolding protein 
known to increase BDNF levels, attenuated alcohol consumption [26]. Together these data 
indicate that BDNF plays an important regulatory role in alcohol consumption and long-term 
usage of alcohol. 
BDNF may influence alcohol intake behavior through modulation of the 
neurotransmitter dopamine (DA), a key component in drug reward and learning processes [8, 
31, 32, 52]. DA transmission in striatal pathways innervating the nucleus accumbens (NAc) and 
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caudate putamen (CPu) is well established in the propagation of addiction related behavior 
through mediating positive reinforcement and habitual learning, respectively [3, 8]. Similar to 
other drugs of abuse, ethanol increases DA in both striatal regions of the CPu and nucleus 
accumbens of the mouse following intraperitoneal (i.p.) administration [5, 29, 34]. Additionally, 
alcoholic patients have less D2 receptors compared to non-alcoholic patients, with this being a 
factor for predisposition to alcoholism or a result of repeated ethanol exposure [36-38]. Mouse 
models using knockouts of the long D2 receptor isoform have suggested that alterations in the 
ratio of long to short D2 receptors are important in regulating ethanol consumption [40]. D2 
receptor expression could be a downstream regulatory target of BDNF, given BDNF’s influence 
on CREB-regulated gene expression and BDNF’s influence on the D2-like receptor D3 [27, 53]. 
BDNF alters DA transmission in neuronal cultures and rescues reduced release of DA in BDNF+/- 
mice [31-33]. Given the evidence that BDNF can regulate alcohol intake and DA transmission, 
the current study aims to understand how BDNF influences the response of the DA system to 
alcohol and how that could modulate alcohol drinking behavior. Additionally, the DA D2 
receptor could be a mediator of BDNF to alter this DA response.  The potential for the DA 
system to undergo more or different alterations in an individual with low levels of BDNF (either 
genetically or environmentally) could be an important factor that may lead one from being a 
casual drinker to becoming dependent. 
  The present work serves as an initial investigation to understand how ethanol consumption 
affects DA transmission in the CPu, specifically aiming to elucidate the role of low endogenous 
BDNF levels on these changes. A modified voluntary consumption drinking protocol known as 
drinking-in-the-dark (DID) [43], was used to examine ethanol consumption. The advantage of 
the DID protocol is it does not require any prior training of the animal or the use of tastants to 
elicit “binge”-like alcohol consumption with pharmacologically relevant blood alcohol levels. 
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Wild-type (WT) and BDNF+/- mice were exposed to 7 days of DID after which aspects of the DA 
system were characterized using pharmacological manipulations using the sampling technique 
microdialysis. Although both genotypes had similar ethanol consumption, the main finding was 
that after 7 days of DID ethanol no longer induced increases in DA levels in the striatum of either 
genotypes. Overall, the BDNF-deficient mice were not subject to more significant alterations of 
the characterized aspects of the DA system following ethanol exposure.  
3.2 Methods 
3.2.1 Animals 
Animals used were offspring from C57BL/6J females and BDNF+/- male mice (50% 
reduction in mRNA and protein), originally purchased from Jackson Laboratory (Bar Harbor, ME, 
USA) that were bred in-house. Genotypes were determined by PCR analysis of tail biopsies as 
previously described [29]. Mice were housed in groups of 4 - 5 on a regular light/dark cycle 
(light: 0600 h – 1800 h). Male mice, 4 - 6 months of age, were used for the described 
experiments. Food and water were available ad libitum except during ethanol drinking sessions 
when mice only had access to food and a single bottle containing ethanol for 2 hours. All 
procedures were designed and conducted to minimize pain and discomfort to the animals. 
Animal care and use was in accordance with the National Institutes of Health Animal Care 
guidelines and approved by the Wayne State University Institutional Animal Care and Use 
Committee. 
3.2.2 Ethanol Consumption 
Approximately 3 weeks before starting the drinking study, all experimental mice were 
moved to reverse light/dark conditions (light: 1800 h – 0600 h); during the last week they were 
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single housed. Voluntary alcohol consumption was measured using a limited access DID model 
[43]. Briefly, 3 hours into the dark cycle (0900 h), the standard water bottle from each cage was 
removed and replaced with a single bottle containing a 15% (v/v in tap water) ethanol solution. 
The ethanol bottle was left in the cage for 2 hours with the room undisturbed, after which it was 
removed and the standard water bottle was returned. The ethanol bottle was weighed before 
and after the drinking session to determine the quantity of ethanol consumed, which was 
reported as grams of ethanol per kilogram of mouse weight, (which was obtained the day 
before DID initiated). This procedure was repeated for a total of 7 days.  
3.2.3 Blood Alcohol Determination 
Blood was collected from the submandibular vein immediately following the last 
drinking session (day 7). Blood alcohol concentrations were determined using a commercially 
available enzymatic assay (Pointe Scientific, Canton, MI, USA). The whole blood method was 
used in which 10 µL blood was homogenized in 90 µL trichloroacetic acid (6.25% w/v). The 
supernatant from this mixture was used for analysis. Absorbance was determined using a 
Shimadzu UV-1800 spectrophotometer. 
3.2.4 Microdiaysis 
Stereotaxic surgeries were performed immediately after the last DID session (day 7) as 
previously described [29, 33]. Briefly, a surgical plane was achieved using isoflurane (3% 
induction, 2% maintenance) anesthetic so that a CMA/7 guide cannula (Harvard Apparatus) 
could be inserted to target the CPu (ML +1.30, AP +1.00, DV -2.50), determined using the mouse 
atlas [54]. The animal’s body temperature was maintained using a heating pad at about 37 ○C. A 
lidocaine (0.5 mg/kg) and bupivacaine (1.5 mg/kg) mixture was subcutaneously injected around 
the incision site to minimize pain before tissue was incised to expose skull. Ophthalmic ointment 
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was applied immediately after anesthetic induction to keep eyes hydrated. The guide cannula 
was secured using dental cement. Following recovery (~3 - 4 h), a CMA/7 microdialysis probe 
(2mm length, 0.24 mm diameter, Cuprophane, 6 kDa cut-off, Harvard Apparatus) was inserted 
and perfused (1.1 µL/min) with sterile artificial cerebrospinal fluid (aCSF; composition: 145 mM 
NaCl, 3.5 mM KCl, 2.0 mM Na2HPO4, 1.0 mM CaCl2, 1.2 mM MgCl2 and pH = 7) continuously until 
experimental dialysis collection the following day. After overnight perfusion with aCSF, baseline 
dialysate samples were collected for one hour at 1.1 µL/min prior to all experimental 
manipulations. After dialysis, brains were removed and sectioned for verification of probe 
placement.    
3.2.4.1 Ethanol and Methamphetamine Microdiaylsis 
Following baseline collections, either 2 g/kg ethanol (15% ethanol solution, v/v in 0.9% 
saline) or 3 mg/kg methamphetamine (METH, Sigma-Aldrich) was injected i.p in mice. 
Microdialysis samples were collected every 20 minutes for 2 or 3 hours after the ethanol or 
METH treatment, respectively. DA content was determined with high-performance liquid 
chromatography (HPLC) equipped with electrochemical detection and results were normalized 
for each mouse as a percent of their respective baseline values. 
3.2.4.2 Quinpirole Microdialysis 
To analyze D2 DA auto-receptor functionality, the dose-dependent effect of the D2 
receptor agonist quinpirole (Sigma Aldrich, St. Louis, MO) on extracellular DA levels was 
measured by perfusing increasing concentrations of the drug (10, 100, and 1000 nM) into the 
CPu using retro-dialysis. Each dose of quinpirole was perfused for one hour during which dialysis 
samples were collected every 20 minutes. DA levels in the presence of drug were determined 
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with HPLC coupled to electrochemical detection and results were normalized for each mouse as 
a percent of their respective baseline values.   
3.2.4.3 Zero Net Flux Microdialysis 
 To determine basal extracellular DA levels, the quantitative microdialysis method of 
zero net flux was used [50]. After baseline samples were collected, varying concentrations of DA 
(5, 10, and 20 nM) in aCSF containing 200 µM ascorbic acid were perfused through the probe for 
90 minutes per concentration through the use of a CMA/402 programmable gradient infusion 
pump. The quantity of DA perfused in (DAin) was determined using in vitro calibration in which 
the same concentrations of DA aCSF were similarly perfused and collected with no animal on 
line [55, 56]. 
3.2.5 Dialysis Sample Analysis 
Following microdialysis collection, DA levels were quantified using HPLC coupled with 
electrochemical detection. An isocratic Shimadzu LC-20AD HPLC pump delivered mobile phase 
to a Phenomenex C18 (2)-HST HPLC column (100 mm x 3 mm, 2.5 um) at a flow rate of 0.4 
mL/min. Mobile phase composition: 75 mM NaH2PO4 monohydrate, 1.6 mM 1-octanesulfonic 
acid, 0.025 mM EDTA, 10% acetonitrile, and 0.002% triethylamine, with a pH of 3 adjusted with 
85% phosphoric acid. A microdialysis sample (20 µL) was injected and DA was measured with an 
ESA 5014B microdialysis cell (E1 = - 150 mV, E2 = +220 mV). A guard cell (ESA 5020) placed in-
line before the injection loop was set to a potential of + 350 mV. Peak areas were integrated and 
quantified against known standards using LC Solutions Shimadzu Software.  
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3.2.6 Data Analysis 
For the DID data, values are reported as grams of ethanol consumed per kilogram of 
mouse weight. For ethanol, METH, and quinpirole dialysis experiments, the percent change in 
DA levels in the presence of drug for each mouse were normalized to their respective baseline 
values (baseline set to 100%). For the zero net flux experiment, a plot was created of the 
concentration of DAin (x-axis) versus the difference between recovered DA (DAout) and DAin on 
the y-axis (DAin – DAout). This plot had four points, one for each DAin concentration which 
included 0, 5, 10, and 20 nM DA, which then had a linear regression fitted to it to give a y = mx + 
b equation. The apparent extracellular concentration of DA (DAext) was determined by the x-
intercept of that line [50]. The extraction fraction (Ed ) was given by the slope (m), which was 
used to assess the in vivo recovery of DA [57]. DAext and Ed values taken from the linear 
regression lines were summarized in bar graphs for statistical testing.  
Data were plotted using GraphPad Prism (GraphPad Software v4) and statistical analysis 
was performed using SPSS (IBM Statistics). Values are reported as mean ± standard error of the 
means (SEMs), with the criteria for statistical significance being p < 0.05. Statistical analysis was 
performed with two-way repeated measures ANOVA for the microdialysis experiments and one-
way repeated measures ANOVA for the drinking data plotted by day. When sphericity was 
violated, the Greenhouse-Geisser correction was used. Two-tailed independent t-tests were 
used for the blood ethanol concentrations and the average daily consumption comparison. 
Finally a two-way independent ANOVA was used to compare the slopes and Cext bar graphs from 
the zero net flux experiment. For repeated measure analysis, missing values were handled using 
SPSS missing value analysis and imputation using the expectation maximization model (EM) 
method. 
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3.3 Results 
3.3.1 Limited Access Ethanol Intake was Comparable Between WT and BDNF+/- Mice   
To assess how alterations in BDNF can influence binge-like drinking in a limited access 
model, DID intake was evaluated in BDNF+/- mice compared to WT littermates. WT and BDNF+/- 
mice were given access to a 15% (v/v in tap water) ethanol solution for 2 hours each day for 7 
days [43]. The average daily consumption (Figure 3.1B) across the 7 days was 2.97 ± 0.19 g/kg 
for WT mice and 2.95 ± 0.13 g/kg for BDNF+/- mice, with no difference observed by an 
independent t-test (t(12) = 0.081, p = 0.937, n = 13/group). No between-subjects effect was 
observed in consumption over the time course of 7 days between genotypes (F(1, 24) = 0.130, p 
= 0.722, Figure 3.1A). However, there was a significant within-subjects effect of time observed 
by one-way repeated measures ANOVA with Greenhouse-Geisser correction (F(3.46, 83.06) = 
6.83, p < 0.001, n = 13 – 15/group), which was comparable with respect to genotypes (Time x 
Genotype interaction, F(3.46, 83.06) = 0.510, p = 0.702) . Because of this difference over time, 
we compared the intake levels of WT and BDNF+/- mice on day 1 and day 7 (Figure 3.1C). Two-
way ANOVA of the day 1 to day 7 comparison showed a main effect of time (F(91,24) = 33.51, p 
< 0.001) with WT and BDNF+/- mice increasing consumption from 2.17 ± 0.21 to 3.43 ± 0.24 g/kg, 
and 2.28 ± 0.14 to 3.09 ± 0.20 g/kg, respectively. BEC values were also not different according to 
the independent t-test, with WT mice at 110.39 ± 30.26 mg/mL and BDNF+/- mice at 76.82 ± 
21.31 mg/mL (t(8) = 0.907, p = 0.391, n = 5/genotype, data not shown).  
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Figure 3.1 Summary of ethanol consumption during DID (n = 13/group) reported as mean ± 
SEMs.  Data for these plots can be found in Table A.1 of the appendix. A) Average daily 
consumption in grams/kilogram of 15 % (v/v) ethanol during the 2 hour DID session over the 
course of seven days. No difference was observed between BDNF+/- and WT mice. There was 
however a main effect of time p < 0.001. B) Average ethanol intake during the entire 7 days of 
DID in g/kg of WT and BDNF+/- mice. C) Comparison of increased consumption from day 1 to day 
7 in WT and BDNF+/- mice where there was a main effect of time p < 0.001.  
3.3.2 Ethanol Induced Increase in DA is No Longer Observed Following Repeated Exposure to 
Voluntary DID Ethanol Consumption in Either WT and BDNF+/- Mice 
DA levels were quantified following an acute injection of 2 g/kg (i.p.) ethanol in naïve 
and 7 day DID WT and BDNF+/- mice. In naïve (control) animals, ethanol treatment similarly 
increased DA levels to about 20 - 25 % over baseline in both WT and BDNF+/- mice (Figure 3.2).  
Baseline DA levels before ethanol was administered were 2.9 ± 0.5 nM and 3.2 ± 0.5 nM in WT 
and BDNF+/- mice, respectively.  After ethanol was administered, there was an approximate 
increase in DA from 100 % to 126 ± 9 % and 120 ± 14 % over baseline at 120 minutes in WT and 
BDNF+/- mice, respectively. In mice given 7 days limited access to ethanol in the DID procedure, 
there was no change in uncorrected baseline values of DA from control mice (1. 7 ± 0.4 nM for 
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WT and 2.5 ± 0.4 nM for BDNF+/- mice). However, an acute injection of ethanol no longer 
elevated DA levels in either genotype (Figure 3.2A & B, n = 7-12/group). Two-way repeated 
measures ANOVA with the Greenhouse-Geisser correction showed no within-subjects effect of 
time (F(4.53, 149.46) = 1.41, p = 0.227) and no interactions between time and genotype (F(4.53, 
149.46) = 0.697, p = 0.612). There was a significant within-subjects interaction between time 
and DID treatment (F(4.53, 149.46) = 3.51, p < 0.01). Between-subjects effects were observed 
for DID treatment (F(1, 33) = 10.07, p < 0.01) but not for genotype (F(1, 33) = 0.019, p = 0.892), 
and there was no genotype x treatment interaction (F(1, 33) = 0.130, p = 0.721)). In naïve WT 
and BDNF+/- animals ethanol is able to increase extracellular DA levels, however after the mice 
have consumed alcohol for 7 days during 2 hour DID sessions ethanol is no longer able to induce 
this increase in DA levels.  
 
Figure 3.2 Ethanol challenge following 7 days of DID had a within-subjects interaction between 
time and treatment (p < 0.01, n = 7-12/group) and a between-subjects effect of treatment (p < 
0.01). DA response to ethanol challenge reported as mean ± SEMs of DA percent of baseline 
following 2 g/kg ethanol challenge. Data for these plots are located in Table A.2 of the appendix. 
A) Naïve WT mice show an increase in DA about 26 % over baseline and WT DID mice show no 
change in DA levels following ethanol challenge. B) Naïve BDNF+/- animals exhibited an increase 
in DA levels of about 20 % over baseline and DID animal show no change. 
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3.3.3 Dopamine Release Stimulated by the Psychostimulant METH was Unaltered Following 7 
Days of DID Ethanol Consumption 
Given that an ethanol challenge did not promote DA release in DID exposed mice, a 
similar experiment was performed with the psychostimulant METH to determine if this 
tolerance to DA stimulation was specific to ethanol. In this experiment, METH was administered 
(3 mg/kg, i.p.) to WT and BDNF+/- naïve mice and mice exposed to 7 days of voluntary DID 
ethanol drinking (Figure 3.3, n = 6 - 12/group). In naïve WT mice, an acute injection of METH 
enhanced DA levels from 1.7 ± 0.3 nM to 20.2 ± 3.2 nM, a 1470 ± 370 % increase relative to 
baseline. METH elicited a similar increase in DA levels, from 2.3 ± 0.5 nM to 23.8 ± 11.1 nM, in 
naive BDNF+/- mice (1120 ± 740 % of baseline). Across the genotypes, mice exposed to 7 days of 
DID ethanol intake showed similar levels of METH-stimulated DA release as naïve controls. WT 
mice following DID had an 1840 ± 480 % increase (from 2.2 ± 0.3 nM to 33.6  ± 6.2 nM) and 
BDNF+/- mice had a 900 ± 300 %  increase (from 2.17 ± 0.38 nM to 25.82 ± 6.66 nM) in DA over 
baseline after acute METH treatment. Analysis by two-way repeated measure ANOVA with the 
Greenhouse-Geisser correction gave a significant within-subjects effect of time (F(1.46, 46.79) = 
35.27, p < 0.001). Within-subjects there was no interaction between time and genotype (F(1.46, 
46.79) = 2.20, p = 0.135), or time and DID treatment (F(1.46, 46.79) = 0.339, p = 0.647). 
Between-subjects there was no significant main effect for genotype (F(1, 32) = 2.41, p = 0.130), 
DID treatment (F(1, 32) = 0.259, p = 0.614), and no interaction between genotype and treatment 
(F(1, 32) = 0.442, p = 0.511). The lack of DA release following ethanol in DID mice of either 
genotype appears to be ethanol specific given that METH was able to increase extracellular DA 
levels in these mice.  
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Figure 3.3 METH challenge following 7 days of DID (n = 6 - 12/group). DA response to a 5 mg/kg 
i.p. injection of METH given at 60 minutes reported as mean ± SEMs of DA percent of baseline.  
Maximal increases over baseline were WT naïve: 1470 ± 370 %, WT DID: 1840 ± 480 %, BDNF+/- 
naïve: 1120 ± 740 % and BDNF+/- DID: 900 ± 300 %.  Responses to METH challenge were not 
different for any of the groups. Data used to create this graph are located in Table A.3 of the 
appendix. 
 
3.3.4 Corrected Basal Extracellular DA Levels and D2-like Auto-receptor Activity Are Not 
Affected by 7 Days of DID Ethanol Consumption in Either Genotype 
Zero net flux was used to determine the apparent basal extracellular DA levels (DAext) 
based on the x-axis intercept of the linear regressions run on plots of recovered DA (DAin – DAout) 
versus perfused DA (DAin) (Figure 3.4A, n = 5 - 6/group). Corrected baseline values of DA were 
similar for all groups regardless of DID treatment or genotype (Figure 4B; WT naïve: 9.0 ± 1.6 
nM, WT DID: 8.8 ± 2.2 nM, BDNF+/- naïve: 8.4 ± 1.8 nM, and BDNF+/- DID: 8.6 ± 1.8 nM) as 
confirmed by two-way independent ANOVA (Figure 3.4B) showing no main effect of genotype 
(F(1, 22) = 0.59, p = 0.810), DID treatment (F(1, 22) = 0.00, p = 0.999), and no interaction of 
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genotype and treatment (F(1, 22) = 0.14, p = 0.906). The Ed did not differ across genotype or 
treatment groups (Figure 3.4C; independent two-way ANOVA, no main effect of genotype (F(1, 
22) = 0.000, p = 0.999), DID treatment (F(1, 22) = 0.09, p = 0.767), or interaction (F(1, 22) = 0.36, 
p = 0.554)). 
 
Figure 3.4 Zero net flux data to determine apparent extracellular DA levels (n = 6 - 8/group). 
Data for these plots is described in Table A.4 of the appendix. A) DAin-DAout plotted versus DAin 
for the zero net flux microdialysis experiment. Above the x-axis there is a net loss of DA from the 
probe to the brain and below there is a net gain of DA into the probe from the brain. The x-
intercept is the apparent extracellular DA concentration (DAext). B) Summary of DAext values with 
no effect for genotype or treatment. C) Summary of the slopes from the zero net flux regression 
lines to indicate DA clearance, again with no affect for genotype or treatment.  
 
The DA D2 receptor has also been implicated in alcohol consumption and dependence in 
both human and mouse studies [39, 40, 58]. Thus far, the mechanistic role of the D2 receptor in 
the pre- and post-synaptic effects of ethanol is unclear. To isolate the presynaptic activity of the 
D2 auto-receptor, the current study evaluated the effect of a D2 agonist quinpirole to attenuate 
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basal DA levels with local perfusion in the CPu using in vivo microdialysis. Quinpirole perfusion 
dose-dependently decreased baseline dialysate DA levels (WT naïve: 1.7 ± 0.3 nM, WT DID: 1.3 ± 
0.1 nM, BDNF+/- naïve: 1.6 ± 0.2 nM, and BDNF+/- DID: 1.7 ± 0.3 nM), with little to no decrease at 
the lowest concentration (10 nM), a ~ 25 % reduction at 100 nM, and a ~ 50% reduction at 1000 
nM (Figure 3.5, n = 7 - 12/group). The quinpirole-mediated reduction in DA levels was similar 
between WT and BDNF+/- naïve mice and mice exposed to 7 days of DID voluntary ethanol 
consumption, indicating that repeated limited access to ethanol drinking did not significantly 
alter auto-receptor activity. Two-way repeated measures ANOVA with the Greenhouse-Geisser 
correction showed a within-subjects effect of time (F(6.33, 189.88) = 32.41, p <0.001), but no 
interaction between time and genotype (F(6.33, 189.88) = 0.908, p = 0.494) or time and DID 
treatment (F(6.33, 189.88) = 1.14, p = 0.339). Between-subjects analysis established no main 
effects for genotype (F(1, 30) = 0.59, p = 0.447), DID treatment (F(1, 30) = 0.70, p = 0.409), or 
interaction (F(1, 30) = 2.68, p = 0.107). The DA system in the CPu appears normal in DID of both 
genotype given that the extracellular levels are not altered and the D2 auto-receptor function is 
normal. 
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Figure 3.5 DA D2-autoreceptor dose-response curves using the agonist quinpirole (n = 7-
12/group). DA response to drug concentrations were reported as mean ± SEMs of DA percent of 
baseline (first hour). Increasing concentrations of quinpirole and the time it was applied are 
indicated on the graph. No genotype or treatment effect was observed but, as would be 
expected, there was a within-subjects effect of time (p < 0.001). Data for this graph are located 
in Table A.5 of the appendix. 
 
3.4 Discussion 
 Given the previously demonstrated role of BDNF in alcohol consumption and addiction 
[21, 23, 24, 26, 29], the present work sought to investigate how alterations to the striatal DA 
system following ethanol consumption may be affected by endogenous BDNF levels. To 
investigate this potential interaction, BDNF+/- mice with a 50% reduction in BDNF protein levels, 
were compared to WT littermates following a well-characterized limited access voluntary 
ethanol consumption protocol, DID. This is the first study to our knowledge that has 
characterized the striatal DA system following repeated voluntary DID ethanol access. Twenty-
four hours after 7 days of DID, WT and BDNF+/- mice were affected similarly by the repeated 
exposure to ethanol. Basal DA levels and D2 auto-receptor function appear normal for both 
48 
 
 
genotypes. There was a loss of ability of ethanol to stimulate DA release after repeated 
exposure that was also similar between genotypes. The lack of ethanol stimulation after 7 days 
of DID highlights how quickly ethanol can cause adaptations in the striatum. Further 
investigations will seek to understand behaviorally what this tolerance means and how BDNF 
levels are affected under similar exposure conditions. 
3.4.1 DID Consumption is Similar for WT and BDNF+/- Mice 
 BDNF+/- mice have increased preference for ethanol, and increased consumption, when 
tested with a 2-bottle choice drinking protocol [26, 28]. Alternatively, the current study, using a 
limited access DID consumption model, did not reveal genotypic differences in ethanol intake or 
the subsequent BEC levels (Figure 3.1). One potential reason for similar consumption between 
genotypes is our use of C57BL/6J mice derived from breeding with BDNF+/- mice as WT controls, 
since this is the background strain of the BDNF+/- mice. The C57BL/6J strain is known to exhibit 
high ethanol intake behavior [44]. The DID model, designed to promote binge-like drinking and 
pharmacologically relevant elevations in blood alcohol levels [47] may mask any elevations in 
drinking behavior driven by BDNF deficiency as animals are reaching a threshold level of 
drinking. Additionally, the limited access to ethanol used in this model is not readily amenable 
to measuring preference due to the animals not having a choice what to drink, which was largely 
altered in previous studies in BDNF+/- mice [26, 28]. Of note, the similar consumption observed 
between WT and BDNF+/- mice (Figure 3.1) does allow for any differential changes in 
neurochemistry following DID to be more easily attributed to endogenously reduced BDNF 
levels, rather than differences in the level of ethanol exposure. 
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3.4.2 There are No Ethanol Induced Increases in DA Following DID for Either WT and BDNF+/- 
Mice 
 Systemic administration of 2 g/kg ethanol in naïve animals elicits an increase in DA levels 
in both striatal regions of the NAc and CPu [29, 34, 35, 59, 60]. The DA increase in the CPu of 
BDNF+/- mice following ethanol challenge is blunted compared to WT littermates [29]. In this 
experiment, DA levels were monitored following an i.p. injection of 2 g/kg ethanol for 2 hours 
similar to the aforementioned study ([29]). Both WT and BDNF+/- control animals showed a 20-
25% increase in DA levels following ethanol injection (Figure 3.2). The lack of genotypic 
differences compared to those previously observed [29] is likely due to differences in 
experimental design. Due to the use of the DID model, all of the neurochemical measurements 
currently presented were conducted during the dark cycle, whereas previous measurements 
were carried out during the light cycle [29]. It is well established that neurochemicals experience 
diurnal variation [61, 62], therefore this change in when experiments were carried out relative 
to light cycles may have contributed to the disparate results. Another potential explanation for 
the genotypic differences no longer being observed is the anesthetic used to perform the 
surgery, which was isoflurane inhalation in the current study and the injectable Avertin 
previously [33]. Although both anesthetics are CNS depressants, there are numerous unknowns 
regarding their molecular targets and their lasting effects [63, 64]. It is plausible that each 
anesthetic could be producing different neuroadaptations before neurochemical measurements 
were made [65, 66]. A major finding of this study was that 7 days of voluntary DID ethanol 
consumption caused alterations in the DA response to a subsequent ethanol challenge, so that 
ethanol-induced DA release was no longer observed in either WT or BDNF+/- mice as compared 
to naïve animals (Figure 3.2). This lack of response to the DA stimulatory effect of ethanol is 
consistent with data that has shown repeated exposure to limited access DID drinking results in 
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a behavioral tolerance to ethanol [67]. In a study by Linsenbardt et al., footslips were counted 
following a 1.5 and 1.75 g/kg ethanol challenge after 16 days of DID consumption: DID exposed 
animals exhibited improved motor performance, in that they demonstrated less hind footslips, 
than their water drinking counterparts [67].  
 In contrast to the lack of ethanol response to DA in DID exposed mice, acute 
administration of the psychostimulant METH produced a robust increase in DA in the CPu, which 
was comparable between DID drinking and naïve WT and BDNF+/- mice. Ethanol has been shown 
to increase DA through enhanced neuronal firing as well as through modulation of other 
neurotransmitters that subsequently act to increase DA [5, 52]. In contrast, METH is a DA 
transporter (DAT) and vesicular monoamine transporter substrate, which together lead to 
reverse transport of DA through DAT, leading to large increases in extracellular DA [5]. The 
observation of METH-induced DA release following DID consumption indicates that the DA 
system is relatively intact and that the tolerance of the DA response to ethanol is specific to the 
pharmacological mechanism underlying DA stimulation by ethanol. While our observation that 
the ‘tolerance’ to the ethanol-evoked DA response was similar in both WT and BDNF+/- mice 
following DID does not implicate a role for BDNF, future studies are planned to understand the 
mechanism underlying this observation. 
3.4.3 Basal DA function is Not Changed Following DID Exposure in Either Genotype 
 The DID procedure is often referenced to promote high ethanol intake over a short 
period of time, reflective of a ‘binge’ pattern of drinking [46, 47]. Few studies to date have 
measured the impact of this pattern of voluntary ethanol consumption on striatal dopaminergic 
function [40, 46, 68]. Additionally, acute ethanol exposure has been shown to alter BDNF mRNA 
and protein expression [26, 29] and BDNF is identified as an important modulator of DA 
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neurotransmission [33]. Taken together, it is reasonable to hypothesize that 7 days of voluntary 
ethanol exposure in the DID model would likely produce alterations in the DA system that would 
be modulated by BDNF.  
First, basal extracellular DA levels were measured using the microdialysis method of 
zero net flux. There was no difference in extracellular DA concentration observed between WT 
and BDNF+/- mice or following DID for either genotype (Figure 4A & B). The fact that DA levels in 
control WT and BDNF+/- animals were not different was unexpected, as previous studies have 
shown a strong genotype dependent difference [33]. The lack of genotypic differences in basal 
levels compared to those previously observed are likely due to differences in experimental 
design as previously discussed (light/dark cycle, surgical anesthetic). Overall, the key finding 
from this characterization was that the DID model of ethanol consumption did not affect 
extracellular DA levels in the CPu. 
In a second set of experiments to assess DA system function, autoreceptor activity was 
evaluated using retro-dialysis of the D2 agonist quinpirole (Figure 5). Alterations in D2 receptor 
levels have been previously reported after ethanol exposure [39, 58], the current experiment 
would isolate the study of presynaptic DA D2 auto-receptor activity changes apart from 
postsynaptic contributions. The maximal effect of D2 autoreceptor inhibition at 1000 nM 
quinpirole infusion resulted in a 50% reduction in dialysis DA levels below baseline. As observed 
with basal DA levels, no difference in DA D2 autoreceptor functionality in the CPu was found 
between genotypes or as a result of DID treatment. A previous study in the NAc reported 
reduced D2 auto-receptor function that was only observed following moderate doses (1.0 g/kg) 
of acute ethanol, but not higher doses (2.0 g/kg); these observations were also true for up to 5 
days of ethanol treatment [39]. The quantity of ethanol consumed using the DID model in the 
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present study (Figure 3.1) is within the higher end of dosing that did not elicit any D2 changes in 
the study by Franklin et al. [39]. The similar DA D2 presynaptic receptor function after DID is 
consistent with our observation that basal extracellular DA levels with zero net flux also remain 
normal. Taken together, 7 days of DID ethanol intake does not have a prolonged effect on tonic 
DA transmission measured 24 hours after the last drinking session.  
3.5 Conclusion 
 Several studies have employed the use of the limited access DID voluntary ethanol 
consumption model to assess the neurobiology of ‘binge’-like drinking as this model produces a 
pharmacologically significant elevation in blood alcohol levels. This study aimed to elucidate the 
neurochemical impact of several days of DID drinking on the DA system in the CPu and evaluate 
the role of BDNF to influence DA transmission after ethanol consumption using BDNF-deficient 
mice. While the current study did not observe any specific changes in drinking behavior or DA 
system function in BDNF+/- mice compared to WT littermates, to support an influence of BDNF 
on ‘binge’-like intake, repeated access to voluntary DID ethanol drinking produced a lack of 
effect in ethanol-stimulated DA release in both WT and BDNF+/- mice. Given the role of striatal 
DA in promoting ethanol drinking behavior, the long-term goal of this work is to understand a 
mechanism for how causal drinking transitions to alcohol dependence in an individual. The DA 
tolerance observed could be an important mediator in the similar consumption observed over 
repeated drinking sessions carried out for several days. If initial drinking sessions produced 
positive effects for the animal, then enhanced consumption in subsequent sessions could be a 
result of the animal trying to attain those positive effects again. Overall the hypothesis that 
BDNF+/- mice would have more significant alterations to their DA system was no supported, 
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however there are neuroadaptations to the DA system that warrant further investigation to 
understand.  
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CHAPTER 4 
Assessment of BDNF-TrkB Signaling in BDNF+/- and WT Mice Following 7 Days of 
DID 
4.1 Introduction  
As a trophic factor, brain-derived neurotrophic factor (BDNF) mediates its responses by 
activation of tropomyosin-related kinase B receptor, also referred to as the tyrosine receptor kinase B 
(TrkB) [10]. Binding of BDNF with the full length (FL) TrkB (FL-TrkB) receptor induces dimerization and 
auto-phosphorylation, which subsequently activates several signaling pathways, most notably mitogen-
activated protein kinase (MAPK), phosphatidylinositol-3-OH kinase (PI3K), and phospholipase Cγ (PLCγ) 
[20, 21]. There is also a truncated TrkB receptor (T-TrkB) whose mode of action is not well understood, 
however there is evidence for its potentiation or attenuation of the FL-TrkB receptor activation 
depending on localization [21, 69, 70]. BDNF has been a protein of interest as a risk factor for alcohol 
use disorder (AUDs), due to the previously discussed findings of its alterations in human alcoholics and 
regulation of ethanol consumption in rodent studies (Chapters 1 and 3). BDNF’s signaling through 
activation of TrkB and downstream targeting of gene transcription make it important in learning and 
memory processes which also make BDNF of interest in addiction research.  
There have been contradicting reports on the effect of ethanol on BDNF protein and BDNF 
mRNA expression levels [26, 29]. A series of investigations from the laboratory of Dorit Ron led to the 
hypothesis that BDNF serves a neuroprotective role by preventing the reinforcing alterations of ethanol 
through increased BDNF-signaling [26, 27, 71]. The caveat of these studies is that they only measured 
BDNF mRNA, while increased mRNA does not necessarily lead to increased protein. Additionally it is 
important to assess the TrkB receptor levels and activation, rather than to infer that increases in BDNF 
mean enhanced receptor activation. In the study by Baek et al., chronic ethanol exposure led to 
reductions in BDNF mRNA in the hippocampus of rats; however there was an up-regulation of the TrkB 
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receptor [30]. The mechanisms behind interactions of BDNF and ethanol are complex and to better 
understand the role of BDNF further investigations should focus on gene and protein expression of the 
protein and its receptor TrkB.  
 The goal of this study was to evaluate BDNF and TrkB following 7 days of binge-like drinking 
using the drinking in the dark (DID) model to understand how low endogenous BDNF levels may lead to 
a propensity for addiction. To this end, mice with a 50 % reduction in the BDNF protein (BDNF+/-) were 
compared to wild-type (WT) littermates following ethanol exposure. The immediate effects were tested 
by assessing changes 30 minutes after the last DID session and lasting effects were assessed 24 hours 
after the last drinking session. Following 7 days of DID, WT mice have reduced BDNF protein levels and 
TrkB activation, whereas the BDNF+/- mice did not exhibit these alterations. These results were surprising 
as we would have expected more alterations from the BDNF+/- mice. The results from this study may 
suggest important implications for the use of the DID model that we had not anticipated.   
4.2 Methods 
4.2.1 Animals 
C57BL/6J (WT) and BDNF+/- mice purchased from The Jackson Laboratory (Bar Harbor, ME, USA) 
were bred in-house and offspring from these breeders were used. The average ages of the male and 
female mice used were 4 – 6 months of age. Genotypes were determined by PCR analysis of tail biopsies 
as previously described (Chapter 2, [29]). Mice were housed in groups of 4 - 5 and maintained on a 
light/dark cycle (light 0600 – 1800 h). Food and water were available ad libitum except during ethanol 
drinking sessions where for 2 hours only ethanol and food were available. All procedures were designed 
and conducted to minimize pain and discomfort to the animals. Animal care and use was in accordance 
with the National Institutes of Health Animal Care guidelines and approved by the Wayne State 
University Institutional Animal Care and Use Committee. 
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4.2.2 Ethanol Consumption 
 Ethanol exposure was achieved using the drinking in the dark (DID) model as previously 
described (Chapter 2). About 2-3 weeks before ethanol exposure, animals were put on a reverse 
light/dark cycle (lights off 0600 h); one week before experiments, animals were placed in singly housed 
conditions for acclimation. Three hours into the dark cycle on DID days the home-cage water bottle was 
removed and replaced with a bottle containing 15 % ethanol (v/v in tap water) for 2 hours per day for 7 
consecutive days. Bottles were weighed before and after DID to determine the grams of ethanol 
consumed per kilogram of mouse weight for each session.  
4.2.3 Tissue Collection  
 Animals were sacrificed by cervical dislocation and subsequent dissection of the brain to isolate 
the caudate putamen (CPu), a sub-region of the striatum. The brain was removed and placed on a petri 
dish covered with an artificial cerebrospinal fluid soaked paper towel. Spatulas and a straight razor were 
then used to section the tissue based on anatomical markers visual to the eye. Tissues were flash frozen 
in liquid nitrogen and stored at -80 ○C until needed for analysis. The time points at which tissues were 
collected from DID mice was 30 minutes and 24 hours after the 7th DID session. Tissue from control mice 
was collected after they had been singly housed for two weeks similar to the DID animals.  
4.2.4 BDNF Protein Quantification 
 BDNF protein levels were determined using a commercially available ELISA assay (Promega, 
Madison, WI). Tissue samples were weighed and homogenized using an ultrasonic cell disruptor. Lysis 
buffer (4 mL/sample) contained: 100 mM PIPES (pH 7.0), 500 mM NaCl, 0.2% (v/v) Triton X-100, 0.1% 
(w/v) NaN3, 2% bovine serum albumin (BSA), 2 mM EDTA and various protease inhibitors (200 µM 
phenylmethanesulfonyl fluoride (PMSF, Sigma, St. Louis, MO), 10 µM leupeptin (Sigma), 0.3 µM 
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aprotinin (Sigma), and 1 µM pepstatin A (Sigma)). After homogenization, samples were centrifuged and 
the supernatants were removed and stored at -80 ○C until analysis.  
Sample analysis was carried out according to the Promega (Madison, WI) kit instructions, with 
each sample analyzed in triplicate. A 96-well plate was incubated overnight at 4 ○C with the anti-BDNF 
monoclonal antibody diluted 1:1000 in carbonate coating buffer (0.025 M sodium bicarbonate and 0.025 
M sodium carbonate, pH 9.7). The following morning the plate was washed once with TBST wash buffer 
(20 mM tris-HCl pH 7.6, 150 mM NaCl, and 0.05% (v/v) Tween 20) and blocked for 1 hour at room 
temperature in 1X sample and block buffer (diluted from 5X stock in kit, cat no. G3311). After blocking 
the plate was washed once with TBST wash buffer before samples (100 µL each) were added. Rows B-H 
of the plate had 100 µL of 1X sample buffer to them and 200 µL of the highest standard (500 pg/mL) was 
added to the standards wells of row A. A 1:2 serial dilution was preformed down the rows of the plate to 
obtain different concentrations of standards for the standard curve (0, 7.8, 15.6, 31.3, 62.5, 125, 250, 
and 500 pg/mL). After standard and sample addition the plate was sealed and incubated for 2 hours at 
room temperature with shaking. The plate was then washed 5 times with TBST wash buffer before the 
anti-human BDNF polyclonal antibody (diluted 1:500 in 1X sample buffer) was added (100 µL) and 
incubated for 2 hours at room temperature with shaking. Again 5 washes with TBST were done and 100 
µL/well of the next antibody was added (anti-IGY horseradish peroxidase conjugate; diluted 1:200 in 1X 
sample buffer) and incubated for 1 hour at room temperature with shaking. During this time the 
3,3´,5,5´-tetramethylbenzidine (TMB) one solution was equilibrated to room temperature. The plate was 
washed 5 times with TBST buffer before the horseradish peroxidase substrate (TMB one solution) was 
added at 100 µL per well and incubated at room temperature for 10 minutes with shaking. Finally the 
reaction was stopped with the addition of 100 µL/well of 1 N HCl and the plate was read on a plate 
reader at 450 nM. From the ELISA assay the concentration of BDNF was determine in units of pg/mL, 
which was multiplied by (4 mL) to determine the pg quantity of BDNF in the sample. The amount of 
58 
 
 
BDNF (in ng) was then divided by the tissue wet weight (ww) recorded before homogenization. The ng 
BDNF quantity divided by the ww (in mg) provided the raw values plotted in Figure 4.2. WT and BDNF+/- 
mice were run on separate plates and kits, thus raw data and values for DID animals normalized to 
percent of control (no ethanol) were both plotted to assess the effects of DID on BDNF levels.  
4.2.5 TrkB Activation and Levels 
 Total TrkB levels and TrkB phosphorylation were determined using immunoblotting. Tissue 
homogenization was achieved using sonication in 100 µL lysis buffer. Lysis buffer contained: 20 mM Tris 
(pH 7.5), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 10% glycerol, protease inhibitors, and 
phosphatase inhibitor cocktails II and III. As before, after homogenization the supernatant was collected 
and stored at -80 ○C until needed. 
 Total protein levels of the homogenates were determined using the enhanced protocol of the 
Pierce™ BCA Protein Assay Kit from Thermo Scientific (Waltham, MA). Samples were diluted 1:100 in 
phosphate buffered saline (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3) before 
use in the assay. Samples were run according to the kit directions in duplicate and transferred to a 96-
well plate and read on a Molecular Devices plate reader at 562 nm. Based on the concentrations 
obtained from the protein assay, samples were diluted in additional lysis buffer such that each sample 
was at a concentration of 2 µg of protein/µL.  
 Samples were mixed with 6X sample buffer/dye (3 g glycerol, 900 mg SDS, 228 mg Tris, and 1.5 
mL beta-mercaptoethanol diluted to 5 mL with water), boiled for 5 minutes at 100 ○C, and loaded onto 
NuPage® pre-cast 4–12% Bis-Tris gels (Life Technologies, Carlsbad, CA). Gels were run in 1X NuPage® 
MOPS (Life Technologies, Carlsbad, CA) running buffer (20X stock: 1.0 M 3-(N-morpholino) propane 
sulfonic acid, 1.0 M tris base, 69.3 mM SDS, and 20.5 mM EDTA) at +127 V for about 1.5 hours. Proteins 
were transferred to a nitrocellulose membrane using a semi-dry transfer apparatus run at +15 V for 40 
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minutes. Membranes were blocked overnight in 5% BSA at 4 ○C. The following day membranes were 
labeled with the primary antibody anti-phospho-NTRK2 (pTyr705) (Sigma-Aldrich, St. Louis, MO) diluted 
1:1000 in 5% BSA overnight at 4 ○C. The secondary anti-rabbit IgG (Cell Signaling, Beverly, MA) HRP-
linked antibody was incubated for one hour the next morning, diluted 1:1000 in 5% BSA. Thermo 
Scientific™ SuperSignal™ West Dura Substrate (Waltham, MA), a luminol-based enhanced 
chemiluminescence (ECL) HRP substrate, was used for detection. The chemiluminescence signal was 
documented on film, which was developed and scanned for band quantification. Blots were stripped 
using Pierce Restore™ PLUS (Thermo Scientific, Waltham, MA) and were blocked for one hour in 5% 
milk. The Neuromics TrkB primary antibody (Edina, MN) was incubated overnight in 5% milk (1:4000 
dilution). Secondary anti-goat (1:4000, Santa Cruz, Dallas, TX) was added for 1 hour and detected as 
before with Thermo Scientific™ SuperSignal™ ECL reagent. The signal for TrkB was too intense for film 
documentation so after a brief 30 second wash a Kodak Imager was used to capture the signal. The blot 
was again stripped with Pierce Restore™ Plus and blocked overnight in 5% milk. The final western was 
for the loading control actin. The actin primary antibody (Sigma-Aldrich, St. Louis, MO) was incubated 
for 1 hour diluted 1:5000 in 5% milk and the secondary anti-rabbit, also in 5% milk (1:2000), was 
incubated for 30 minutes. Enhanced chemiluminescence reagent was again used and documented using 
film.  
4.2.6 Statistical and Data Analysis  
 BDNF levels were normalized to tissue wet weight, TrkB levels were normalized to actin or as a 
ratio of phosphorylated to total levels and DA tissue content concentrations were normalized to total 
protein levels. Bands for the Western blots were quantified using ImageJ software (NIH, Bethesda, MD). 
GraphPad Prism v5 software was used to create graphs and run statistical analysis using two-way 
ANOVA, with significance set to p < 0.05. 
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4.3 Results 
4.3.1 Ethanol Consumption 
 Ethanol consumption over the course of 7 days of DID was similar between WT and BDNF+/- mice 
(Figure 4.1). Analyzing all DID consumption data together (Figure 4.1A, repeated-measures two-way 
ANOVA) there was a within-subjects effect of time (F(6,210) = 3.01, p < 0.01). Together there was also a 
between-subjects effect of gender (F(1,35) = 16.95, p < 0.001) and genotype (F(1,35) = 5.27, p < 0.05). 
The within-subjects effect of time is attributed to the males based on a separate analysis of the genders 
showing a significant effect for males only (F(6,114) = 3.09, p < 0.01, Figure 4.1B). The genotypic effect 
can be attributed mainly to the female animals (Figure 4.1C) as a separate genotype analysis on males 
(F(1,19) = 1.01, p = 0.33) and females (F(1,14) = 3.90, p = 0.07) did not show significance for either 
gender, but there was a trend with females based on their p-values.  
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Figure 4.1 Ethanol intake during the 7 days of DID in grams (g) of ethanol consumed per kilogram (kg) of 
mouse weight (n = 9–13/group). A) All genotypes and genders plotted together showing a main effect of 
gender (p < 0.001) and genotype (p < 0.05). B) Ethanol intake for male mice only with a main effect of 
time (p < 0.01). C) Ethanol intake for female mice with a trend towards genotypic differences (p = 0.07). 
Data to create these plots can be found in Table A.6 and A.7 of the appendix. 
 
4.3.2 BDNF Levels 
 BDNF levels were determined using an ELISA assay. Due to the variability in assay kits and the 
fact that different kits were used for WT and BDNF+/- mice, raw values and values as percent of control 
for naïve animals were calculated to better assess the effect of DID. BDNF levels plotted for both 
genders as ng BDNF/mg wet weight (ww) show a reduction in BDNF levels in both genotypes (Figure 
4.2A). Two-way ANOVA illustrated a main effect of treatment (F(2,46) = 3.70, p < 0.05) and of genotype 
(F(1,46) = 31.08, p< 0.001). Bonferroni post-test revealed that WT controls were significantly different 
from the 24 hour treatment group (p < 0.05). Plotting the data as percent of control for naïve animals of 
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their own genotype (Figure 4.2B), the effect of genotype was no longer observed (as expected) but the 
confidence of the main effect of treatment increased (F(2,45) = 6.43, p < 0.01). Normalized data gives a 
clearer indication of the effect of DID, which was similar for both WT and BDNF+/- mice. In WT animals 
there was an almost 25% reduction in BDNF levels 30 minutes after the last DID session which was 
further attenuated 24 hours after the last DID session. BDNF+/- mice had reduced BDNF levels (~60 % of 
baseline) 30 minutes after the last DID session; a similar reduction was observed at 24 hours as well.  
The aforementioned data included both genders for each genotype. Figure 4.2C-F shows similar 
comparisons of raw versus normalized data with the genotypes also separated out by gender. WT males 
and females appear to undergo similar reductions in BDNF levels, however in BDNF+/- mice the 
previously observed reductions of BDNF are clearly attributed to the females. Figure 4.2C, comparing 
raw values of male WT and BDNF+/- mice shows that there was a main effect of genotype (F(1,25) = 
18.87, p < 0.001) and the difference between WT mice from the control group and the 24 hours group 
was significant (Bonferroni post-test, p < 0.05). In the normalized data set, (Figure 4.2D), the main effect 
of genotype was not observed but the reduction in 24 hour WT animals was still significant (Bonferroni 
post-test, p < 0.05). Raw BDNF levels for female animals (Figure 4.2E) had a main effect of genotype only 
(F(1,13) = 9.22, p < 0.01). WT females had a similar trend in attenuated BDNF levels following the DID 
protocol as the male WT mice. However, the female BDNF+/- mice appeared to be more heavily impacted 
by DID than their male BDNF+/- counterparts. When BDNF levels were normalized for female mice 
(Figure 4.2F) there was a significant main effect of treatment (F(2,13) = 15.32, p < 0.001) and genotype 
(F(1,13) = 5.46, p < 0.05). Female BDNF+/- mice had a significant reduction in BDNF at 30 minutes and 24 
hours as compared to their controls (Bonferroni post-test, 30 minutes p < 0.05, 24 hours p < 0.001).   
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Figure 4.2 BDNF levels reported as raw values (ng BDNF/wet weight (ww) of tissue) and normalized 
based on assay plate to control animals. Mixed gender (A&B, n = 6-8/group) and separate gender plots 
(C-F, n = 2-5/group). Significant differences observed by Bonferroni post-test are displayed on graphs (* 
p < 0.05, *** p < 0.001). A) WT and BDNF+/- levels of BDNF protein with mixed gender. There was a main 
effect of treatment (p < 0.05) and of genotype (p < 0.001). B) Mixed gender plot of BDNF levels 
normalized to control animals for each genotype where a main effect of DID treatment was observed (p 
< 0.01). C) BDNF levels for male animals only, where there was a main effect of genotype (p < 0.001). D) 
Normalized BDNF levels for male mice. E) BDNF levels in female mice where there was a main effect of 
genotype (p < 0.01). F) Normalized BDNF levels in female mice with a main effect of genotype (p < 0.05) 
and treatment (p < 0.001). Data to create these plots can be found in Table A.8 of the appendix. 
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4.3.3 TrkB Levels and Activation 
 TrkB levels and activation were assessed using two separate blots for male vs. female animals. 
Each genotype/treatment group contained 2–3 mice. Activation was assessed by determining 
phosphorylated levels of TrkB (p-TrkB), which were observed for both the T-TrkB (truncated) and FL-TrkB 
(full length). Total truncated and full length levels of TrkB were also evaluated. Figures 4.3 and 4.5 
summarize each of these protein measurements, which were normalized to the actin loading control for 
male and female mice, respectively. Figures 4.4 and 4.6 summarize the ratios between phosphorylated 
TrkB to total TrkB for both truncated and full length for male and female mice, respectively. Additionally, 
the ratios of the phosphorylated (Figure 4.4C and 4.6C) and total levels (Figure 4.4D and 4.6D) of the two 
receptors are also plotted.  
4.3.3.1 Males 
 Phosphorylation of FL-TrkB was similar for all groups of male WT and BDNF+/- mice with no main 
effects (two-way ANOVA, Figure 4.3A) of treatment or genotype observed, however there was a 
significant reduction of p-FL-TrkB 30 minutes after DID for the WT animals only (Bonferroni post-test, p < 
0.05). Total FL-TrkB levels are not different for either genotype (Figure 4.3C). Activation of T-TrkB had a 
divergent pattern at the 30 minute time point, with a decrease in WT and an increase in BDNF+/- mice 
(Figure 4.3B). There was a main effect of genotype (F(1,10) = 7.52, p < 0.05) on p-T-TrkB and a significant 
interaction of genotype x treatment (F(2,10) = 7.39, p < 0.05). The reduction of p-T-TrkB observed in WT 
male’s was not statistically different in the post-test but the increase at 30 minutes in BDNF+/- mice was 
significant (Bonferroni, p < 0.05). For both WT and BDNF+/- male mice p-T-TrkB levels returned to control 
by 24 hours after DID. Finally, for total T-TrkB (Figure 4.3D), there was an increase in levels at the 30 
minute and 24 hour time point for WT mice as compared to control (Bonferroni post-test, 30 minute p < 
0.01, 24 hour p < 0.05), leading to a main effect of treatment (F(2,10) = 7.403, p < 0.05) and genotype 
(F(1,10) = 9.43, p < 0.05) in the two-way ANOVA. Additionally based on the increases in T-TrkB following 
65 
 
 
DID in the WT and no change in the BDNF+/- mice there was a significant treatment x genotype 
interaction (F(2,10) = 5.75, p < 0.05).   
 
 
Figure 4.3 Phosphorylation of full-length and truncated TrkB receptor, as well as total levels observed 
from western blot analysis, all normalized to actin in male animals (n = 2-4/group). Only significant 
differences observed by post-test are displayed on graphs (* p < 0.05, ** p < 0.01). A) Phosphorylated 
levels of the full length TrkB receptor (p-FL-TrkB). B) Phosphorylation of the truncated receptor (p-T-
TrkB) in which there was a main effect of genotype (p < 0.05) and a genotype x treatment interaction (p 
< 0.05). C) Total full-length TrkB levels in which no statistical significance was observed. D) In total 
truncated receptor levels (T-TrkB) there was a main effect of treatment (p < 0.05), genotype (p < 0.05) 
and treatment x genotype interaction (p < 0.05). Data to create these plots can be found in Table A.9 
and Figures: A.1, A.3 and A.5 of the appendix. 
 
66 
 
 
To assess receptor activation, the ratios of p-T-TrkB/total T-TrkB and p-FL-TrkB/total FL-TrkB 
were calculated. The ratio of p-FL-TrkB/total FL-TrkB was reduced at 30 minutes in WT mice (Bonferroni, 
p < 0.05, Figure 4.4A) however there was no main effect of treatment. There was also a reduction in p-
FL-TrkB/total FL-TrkB in BDNF+/- control mice compared to WT controls that also did not produce any 
main effect of genotype (p = 0.094, Figure 4.4A). The ratio of p-T-TrkB/total T-TrkB (Figure 4.4B) appear 
to trend toward a decrease in WT mice and increased in BDNF+/- mice at 30 minutes (Bonferroni, p < 
0.05) and levels are comparable to control by 24 hours. This divergent response led to a main effect of 
genotype (F(1,10) = 8.48, p < 0.05) and interaction between genotype x treatment (F(2,10) = 8.14, p < 
0.01). The ratio of p-FL-TrkB to p-T-TrkB was calculated and no statistically significant changes were 
detected (Figure 4.4C), however there is trend towards BDNF+/- mice having a smaller ratio (p-FL-TrkB/p-
T-TrkB) due to the increases of the p-T-TrkB observed after DID at both 30 minutes and 24 hours. Finally, 
the ratio of total TrkB receptor was determined for FL-TrkB compared to T-TrkB and there was a main 
effect of genotype (Figure 4.4D, F(1,10) = 8.01, p < 0.05), based on the increase in BDNF+/- controls 
compared to WT controls and also the increased levels at 30 minutes in the BDNF+/- mice. 
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Figure 4.4 Receptor activation in male mice indicated by the ratio of the phosphorylated 
receptor to the total receptor levels. Separate ratios of phosphorylated receptors and total 
levels are also shown (males, n = 2-4/group). Only significant differences as determined by post-
test are displayed on graphs (* p < 0.05). A) Phosphorylated levels of the full length TrkB 
receptor (p-FL-TrkB) divided by total full length levels (FL-TrkB). B) Phosphorylation of the 
truncated receptor (p-T-TrkB) divided by total truncated receptor (T-TrkB) levels where there 
was a main effect of genotype (p < 0.05) and a genotype x treatment interaction (p < 0.01). C) 
Ratio of full length (p-FL-TrkB) to truncated (p-T-TrkB) phosphorylated receptors. D) Ratio of 
total receptor levels full length (FL-TrkB) to truncated (T-TrkB) where there was a main effect of 
genotype (p < 0.05). Data to create these plots can be found in Table A.9 and Figures: A.1, A.3 
and A.5 of the appendix. 
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4.3.3.2 Females 
 Given the gender differences observed in the BDNF levels, and the space constraints of 
the protein gel, TrkB levels were assessed separately for the female mice. Female BDNF+/- mice 
had slightly lower levels of phosphorylation of FL-TrkB compared to WT mice (two-way ANOVA 
main effect of genotype, F(1,12) = 14.16, p < 0.01, Figure 4.5A). There was no statistically 
significant effect of treatment on p-FL-TrkB, however, at the 30 minute and 24 hour time points, 
p-FL-TrkB levels did show a trend toward reductions in female BDNF+/- mice. With respect to 
total FL-TrkB levels in females (Figure 4.5C) the changes were similar yet more pronounced than 
the male mice. In female WT mice, total FL-TrkB levels were increased at the 30 minute and 24 
hour DID groups (Bonferroni, 30 minute p < 0.05, 24 hour p < 0.01). BDNF+/- control mice had 
enhanced levels of FL-TrkB compared to WT controls and also had increase total FL-TrkB 30 
minutes after DID as compared to BDNF+/- control (Bonferonni, p < 0.001). These changes in total 
FL-TrkB led to a main effect of treatment (F(1,12) = 16.63, p < 0.001), genotype (F(1,12) = 8.58, p 
< 0.05), and a genotype x treatment interaction (F(2,12) = 7.57, p < 0.01) in the two-way ANOVA 
(Figure 4.5C). With respect to phosphorylation of the T-TrkB receptor (Figure 4.5B), there was a 
main effect of genotype (F(1,12 = 81.06, p < 0.001), as well as a genotype x treatment 
interaction (F(2,12) = 8.70, p < 0.01). In female BDNF+/- control mice p-T-TrkB levels were 
reduced compared to WT animals, and there was a significant reduction in p-T-TrkB levels at 30 
minutes and 24 hours after DID (Bonferroni, 30 minutes p < 0.05, 24 hours p < 0.01). Total T-
TrkB levels were similar for control animals, but there was a main effect of treatment (Figure 
4.5D, F(2,12) = 12.56, p < 0.01) given the increase in total T-TrkB levels following DID, which 
were more pronounced in BDNF+/- mice at both 30 minutes and 24 hours after DID (Bonferroni, 
30 minute p < 0.01, 24 hours p < 0.001).  
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Figure 4.5: Phosphorylation of full-length and truncated TrkB receptor, as well as total levels 
observed from western blot analysis, all normalized to actin in female animals (n = 2-4/group, 
Bonferroni post-test, * p < 0.05, ** p < 0.01, *** p < 0.001). A) Phosphorylated levels of the full 
length TrkB receptor (p-FL-TrkB), where there was a main effect of genotype (p < 0.01). B) 
Phosphorylation of the truncated receptor (p-T-TrkB), where there was a main effect of 
genotype (p < 0.001) and a genotype x treatment interaction (p < 0.01). C) Total full-length TrkB 
(FL-TrkB) levels where there was a main effect of treatment (p < 0.001), genotype (p < 0.05) and 
treatment x genotype interaction (p < 0.01). D) Total truncated receptor levels (T-TrkB) in which 
there was a main effect of treatment (p < 0.01). Data to create these plots can be found in Table 
A.10 and Figures: A.2, A.4 and A.6 of the appendix. 
 
The activation of the FL-TrkB, as assessed by the ratio of p-FL-TrkB to total FL-TrkB 
(Figure 4.6A), exhibited a main effect of genotype (F(1,12) = 25.83, p < 0.001), treatment (F(2,12) 
= 21.98, p < 0.001), and an interaction of genotype x treatment (F(2,12) = 4.65, p < 0.05). Post-
hoc analysis revealed a significant reduction of FL activation (p-FL-TrkB/FL-TrkB) at the 30 
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minute time point for both genotypes, where in the WT mice this reduction was persistent for 
up to 24 hours. The ratio of p-T-TrkB to total T-TrkB had a main effect of genotype (F(1,12) = 
13.06, p < 0.01) and treatment (F(2,12) = 12.66, p < 0.01) with post-tests showing a statistically 
significant reduction of p-T-TrkB/T-TrkB at 30 minutes and 24 hours after DID in female BDNF+/- 
mice. The ratios of p-FL-TrkB to p-T-TrkB were unaltered for WT mice, while in female BDNF+/- 
mice they were increased only 24 hours after DID (Figure 4.6C, Bonferroni post-test, p < 0.001). 
Due to the increase in p-FL-TrkB/p-T-TrkB at 24 hours for the female BDNF+/- there was a main 
effect of genotype (F(1,12) = 23.78, p < 0.001), treatment (F(2,12) = 7.71, p < 0.01) and genotype 
x treatment interaction (F(2,12) = 11.89, p < 0.01). The ratios of the total FL-TrkB levels to total 
T-TrkB (Figure 4.6D) had a significant interaction of genotype x treatment only (F(2,12) = 6.77, p 
< 0.052) due to the divergent pattern of: increases in female WT treated animals versus 
decreases in treated BDNF+/- mice at 24 hours. The post-hoc analysis revealed a statistical 
difference from control to 24 hours in the BDNF+/- mice (p < 0.01).  
 
71 
 
 
 
Figure 4.6: Receptor activation indicated by the ratio of the phosphorylated receptor to the total 
receptor levels. Separate ratios of phosphorylated receptors and total levels are also shown 
(females, n = 2-4/group). Only significant differences observed by post-test are displayed on 
graphs (* p < 0.05, ** p < 0.01, *** p < 0.001). A) Phosphorylated levels of the full length TrkB 
receptor (p-FL-TrkB) divided by total full length levels (FL-TrkB) where there was a main effect of 
genotype (p < 0.001), treatment (p < 0.001) and a genotype x treatment interaction (p < 0.05). B) 
Phosphorylation of the truncated receptor (p-T-TrkB) divided by total truncated receptor levels 
(T-TrkB) where there was a main effect of genotype (p < 0.01) and treatment (p < 0.01). C) Ratio 
of phosphorylated full length (p-FL-TrkB) to truncated (p-T-TrkB) receptors, where there were 
effects of genotype (p < 0.001), treatment (p < 0.01), and a genotype x treatment interaction (p 
< 0.01). D) Ratio of total receptor levels, full length (FL-TrkB) to truncated (T-TrkB), where there 
was a treatment x genotype interaction (p < 0.05). Data to create these plots can be found in 
Table A.10 and Figures: A.2, A.4 and A.6 of the appendix. 
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4.3.3.3 Summary Tables 
Tables 1–4 summarize the aforementioned differences observed in total receptor levels, 
activation and the various ratios determined. The smaller symbol size in these comparison 
tables indicates a trend towards differences. Fluctuations that were not statistically significant 
but appear qualitatively different (by visual observation) are highlighted in red.  
Table 4.1 Summary of changes in BDNF and its receptor TrkB for male BDNF+/- controls and DID 
WT animals as compared to male WT control animals. 
Protein Measure BDNF+/- Control WT 30 min WT 24 hour 
BDNF ↓ ↓ ↓ 
Total Truncated TrkB = ↑ ↑ 
Total Full Length TrkB ↑ ↑ ↑ 
pTrkB (truncated) = ↓ = 
pTrkB (full length) = ↓ = 
p-FL/Total FL TrkB ↓ ↓ ↓ 
p-T/Total T TrkB = ↓ = 
pFL/pT = = ↓ 
FL/T ↑ = = 
 
Table 4.2 Summary of changes in BDNF and TrkB for male BDNF+/- DID mice as compared to 
control animals. 
Protein Measure BDNF+/-  30 
min 
BDNF+/-  24 
hour 
BDNF = = 
Total Truncated TrkB = ↑ 
Total Full Length TrkB = = 
pTrkB (truncated) ↑ ↑ 
pTrkB (full length) = = 
p-FL/Total FL TrkB = = 
p-T/Total T TrkB ↑ = 
pFL/pT ↓ ↓ 
FL/T = ↓ 
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Table 4.3 Summary of changes in BDNF and TrkB for female BDNF+/- controls and DID WT 
animals as compared to female WT control animals. 
Protein Measure BDNF+/- Control WT 30 min WT 24 hour 
BDNF ↓ ↓ ↓ 
Total Truncated TrkB = ↑ ↑ 
Total Full Length TrkB ↑ ↑ ↑ 
pTrkB (truncated) ↓ = ↑ 
pTrkB (full length) ↓ = = 
p-FL/Total FL TrkB ↓ ↓ ↓ 
p-T/Total T TrkB = ↓ ↓ 
pFL/pT = = = 
FL/T ↑ ↑ ↑ 
 
Table 4.4 Summary of changes in BDNF and TrkB for female BDNF+/- DID animals as compared to 
control animals. 
Protein Measure BDNF+/-  30 
min 
BDNF+/-  24 
hour 
BDNF ↓ ↓ 
Total Truncated TrkB ↑ ↑ 
Total Full Length TrkB ↑ = 
pTrkB (truncated) ↓ ↓ 
pTrkB (full length) ↓ ↓ 
p-FL/Total FL TrkB ↓ = 
p-T/Total T TrkB ↓ ↓ 
pFL/pT = ↑ 
FL/T = ↓ 
 
4.4 Discussion 
 The data obtained from the various tissue content analyses allows for genotypic 
comparisons of the effect of DID on BDNF-TrkB signaling, as well as the role of gender in these 
alterations. The primary goal of these experiments was to understand how voluntary ethanol 
consumption through DID influences BDNF-TrkB signaling in mice with low endogenous BDNF 
levels compared to normal (WT) mice. Understanding how ethanol may alter BDNF-deficient 
mice differently than WT mice may lead to a better understanding of the risk associated with 
humans having mutations in their BDNF gene. An additional piece of information was assessed 
74 
 
 
in these studies to determine if gender may lead to different alterations in the effects of DID on 
WT and BDNF+/- mice. The four groups under study, male WT, male BDNF+/-, female WT and 
female BDNF+/-, all seem to have slightly different alterations to BDNF and TrkB following 7 days 
of DID. The changes observed help to understand the role of low endogenous BDNF levels by 
suggesting that corresponding TrkB changes also occur; but also highlight a need to study both 
sexes in order to better relate to the human condition.  
4.4.1 DID Behavior is Similar Between WT and BDNF+/- Mice 
 Ethanol consumption was assessed for 7 days, after which protein measures were made 
to determine BDNF-TrkB signaling function. WT and BDFN+/- mice exhibited similar ethanol 
consumption however there were some gender based differences. The main effect of genotype 
observed when all mice were assessed together (statistically) was likely attributed to the female 
WT mice because of their higher consumption on days 1 – 4. By the end of the 7 days however, 
consumption for all of the groups was similar. For the present study the focus was on genotype 
and the male and female mice were assessed separately, therefore there is less emphasis on 
drinking differences observed between male and female mice.  
4.4.2 DID Induced Reductions in BDNF Levels Lead to Reductions in Activation of the TrkB 
Receptor  
 BDNF levels were initially analyzed with the intention of using male and female mice 
together to assess the effect of DID (due to limited availability from the mouse colony), however 
other experimental factors led us to assess gender separately (see following). Initially, it 
appeared that BDNF levels were reduced to about 60% of baseline for both WT and BDNF+/- 
mice (Figure 4.2A & B). However, separation of data obtained from male and female mice 
indicated that the reduced BDNF levels following DID in BDNF+/- mice were primarily due to the 
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response of the female mice (Figure 4.2D & F), since a 50% (30 minutes) and 90% (24 hours) 
decrease was observed in females with no change in the males. In contrast, in the WT animals 
the reductions in BDNF levels were attributed mainly to male animals, especially at 30 minutes 
after the 7th DID session.  
 For the TrkB receptor, investigations primarily focused on the ratio of p-FL-TrkB to total 
FL-TrkB; with this ratio considered as activation of TrkB signaling by BDNF. The changes in 
receptor activation (p-FL-TrkB/FL-TrkB) were consistent with the changes observed in BDNF 
protein levels. In both male and female WT mice, there was a reduction in receptor activation at 
both 30 minutes and 24 hours after the 7th DID session. Although the mechanism of how the 
ratios of p-FL-TrkB/FL-TrkB are reduced to indicate attenuated TrkB activation in WT mice are 
different. The levels of phosphorylation (p-FL-TrkB) are consistent following treatment, whereas 
the amount of total receptor (FL-TrkB) was increased. This trend of stable p-FL-TrkB and 
increased FL-TrkB was true except at the 30 minute time point in male WT mice, where 
phosphorylation is reduced leading to the reduction in p-FL-TrkB/FL-TrkB. For BDNF+/- control 
mice of both genders, there was a reduction of FL-TrkB activation compared to WT animals and 
this reduction was a result of increased levels of total FL-TrkB. In BDNF+/- male mice there was 
no difference in BDNF levels or FL-TrkB activation following DID exposure. BDNF+/- females had 
attenuation in BDNF levels: to 50% at 30 minutes and 10% at 24 hours, compared to BDNF+/- 
controls. Interestingly, reductions in FL-TrkB activation for female BDNF+/- mice were only 
observed at the 30 minute time point due to slightly lower p-FL-TrkB levels and increased total 
FL-TrkB. By 24 hours, the total FL-TrkB levels are back to control levels suggesting that reduced 
BDNF levels 24 hours after the last DID session are not translating to alterations in signaling. The 
gender differences observed with regard to BDNF and TrkB levels in BDNF+/- mice only could 
likely be a result of differences in gene expression due to estrogen regulation, which has 
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previously been shown [72]. Further experiments should verify the gender differences observed 
in BDNF+/- mice by increasing the n-values in the study for example. Overall these data suggest 
that the reduced BDNF levels, whether endogenous or as a result of DID exposure, yield 
reductions in receptor activation due primarily to increases in the total amount of FL-TrkB 
expression.   
 The role for BDNF in mediating ethanol’s action and the affect ethanol has on BDNF is 
difficult to understand due to seemingly conflicting evidence. First, numerous studies have 
pointed to a neuroprotective role for BDNF due to its increased expression following ethanol 
exposure, as well as reductions in BDNF leading to enhanced ethanol consumption [26, 28].  
However, many of the studies indicating increased BDNF levels following ethanol exposure 
examined only mRNA levels, not protein. When acute ethanol has been administered, BDNF 
protein levels are reduced 45 minutes after administration [29]. The divergence in mRNA and 
BDNF protein levels could be a result of ethanol’s action on different neuronal sub-populations. 
For instance, despite the diffuse expression of BDNF throughout the brain, the main source of 
BDNF in the CPu is from glutamatergic cortical afferents [73]. One molecular target of ethanol is 
the glutamatergic N-methyl-D-aspartate (NMDA) receptor, which leads to neuronal inhibition 
[74], through which BDNF levels in the CPu could be reduced (recall Figure 1.5). With regard to 
enhanced BDNF mRNA following acute ethanol, it has been established that TrkB activation can 
be switched from a transient to sustained activation mode when coupled with neuronal 
depolarization [75]. Acute administration of ethanol increases extracellular DA levels in the CPu 
which could lead to sustained activation of TrkB, despite reduced BDNF levels. This sustained 
activation of TrkB could lead to increased BDNF mRNA expression through its downstream 
target of the CREB transcription factor which can regulate BDNF transcription. Together these 
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studies suggest that despite the conflicting mRNA and protein measures of BDNF, following 
ethanol exposure the neuroprotective pathway for BDNF in response to ethanol is still valid.  
Given the hypothesis that BDNF is serving a neuroprotective role in acute ethanol 
exposure, what does it mean when WT mice have reduced BDNF and TrkB activation following 
repeated ethanol exposure with 7 days of DID? The immediate and sustained reductions in 
BDNF and TrkB activation in WT mice following 7 days of DID shown here suggest that the DID 
model may be promoting an alcohol dependent phenotype in the WT animals. A study by Logrip 
et al. used a variation of the DID procedure, where mice had 4-hour daily DID sessions with 
access to water and ethanol for 6 weeks [76]. Key findings were increased ethanol preference 
over time in WT animals, and disruption in the proposed BDNF protective pathway [76]. Initially, 
after 1 day of modified DID consumption BDNF mRNA was increased in the CPu only, however 
after 6 weeks there were no longer any differences observed in BDNF mRNA in the CPu and 
there was reduced expression in the cortex [76]. The reduced BDNF-TrkB signaling in our WT 
mice may indicate an earlier onset of dysfunction in the protective BDNF pathway than the 
aforementioned 6 weeks. Additionally the inherent nature of the DID procedure to produce 
excess ethanol consumption and blood alcohol concentrations, could result in initiating an 
addiction or dependence in the WT animals. If dependence in WT animals is being induced this 
complicates our use of the BDNF+/- mice to assess the role of low endogenous BDNF levels to 
make one more susceptible to alcohol dependence because we have caused dysfunction in our 
control group that we are comparing too. The goal of using the BDNF+/- mice was to understand 
how alterations may occur faster or to a greater extent than their WT counterparts, however if 
our use of the DID model for 7 days is rendering a dysfunction in the WT animals than this 
model or exposure length may not be optimal for our purposes. Further support for the 7 days 
of DID producing a dependence-like phenotype can be found when considering the enhanced 
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preference for ethanol consumption in the BDNF+/- mice. Other ethanol consumption models 
have shown increased preference and consumption in the BDNF+/- mice [26, 28] likely due to 
their already altered BDNF-TrkB signaling as compared to WT. The increase in ethanol 
preference observed in WT mice by Logrip et al. after 6 weeks in a modified DID protocol, 
together with alterations in the neuroprotective BDNF pathway [76], suggest that DID is 
producing a similar phenotype to the BDNF+/- mice. Although, further investigations are required 
to assess these hypotheses, together the present investigations and previous studies show that 
disruptions in BDNF-TrkB signaling have an impact on ethanol consumption and conversely 
ethanol causes alterations to the important neurotrophic factor BDNF. 
An essential component to further studies which could test the hypothesis of 7 days of 
DID causing addiction/dependence in WT animals, would be to incorporate a behavioral 
assessment of the preference for or the seeking of ethanol in WT or BDNF+/- mice. If the goal is 
to understand what neuroadaptations switch a casual drinker to a dependent (or addicted) 
drinker, than assessing the animals after they have become addicted is not as useful. Future 
studies should focus on intermediate time points throughout the DID exposure, as well as a 
behavioral component to assess the animals preference for ethanol in order to infer if an 
addiction/dependence is being created in the animal. Another consideration is the numerous 
intracellular signaling cascades induced by TrkB activation and the different biological responses 
resulting from those pathways. There is evidence that different cascades are affected differently 
by ethanol and as such in order to truly understand the implications of altered BDNF-TrkB 
signaling, the specific downstream pathways up-regulated or down-regulated must be 
investigated in detail [21]. Finally, most of the reductions in TrkB activation resulted from 
increases in total FL-TrkB levels; therefore, when repeated ethanol exposure down-regulates 
BDNF protein levels, it would be important to understand what specific mechanism is 
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responsible for enhanced TrkB receptor expression. Similarly there should be a confirmation 
that the reduced activation observed in the ratios, actually leads to attenuation of the pathways 
downstream of TrkB.  
4.4.2.1 An Alternative Explanation for the Alterations in BDNF-TrkB Signaling. 
 Most studies discuss the outcome of enhanced BDNF-TrkB signaling and how this 
promotes synaptic plasticity and learning [77]. It is possible that the reductions in BDNF-TrkB 
signaling in WT animals are actually serving to reduce synaptic plasticity in the presence of 
repeated exposure to ethanol to prevent reinforcement of its addictive properties. Despite the 
fact that BDNF-TrkB signaling is reduced in BDNF+/- males compared to WT, 7 days of DID did not 
cause further attenuations, which could indicate their genetic susceptibility to addiction. If 
reductions in BDNF-TrkB signaling were considered protective then the unchanged BDNF-TrkB 
signaling in the male BDNF+/- mice following DID may indicate that they are more amenable to 
the re-enforcing properties of ethanol. Future studies could investigate this behaviorally by 
assessing learning and memory in the WT and BDNF+/- males following 7 days of DID. 
4.4.3 Differences in T-TrkB Are Acute and Less Dependent on BDNF Levels 
 There is less known about the T-TrkB receptor, its activation, and what that activation 
means for cellular responses. Although the role of the T-TrkB receptor is not well understood, 
we chose to pursue assessing T-TrkB levels to provide additional insight into the interactions of 
BDNF and ethanol. T-TrkB receptor activation was not different between control WT and BDNF+/- 
mice, whereas FL-TrkB receptor activation was reduced in the BDNF+/- controls compared to WT. 
In WT males there was a trend toward reduced activation (p-T-TrkB/T-TrkB) at only 30 minutes 
due to reduced phosphorylation and increased total T-TrkB levels. In female WT animals, there 
was a slight reduction in T-TrkB activation due to increased total T-TrkB levels. BDNF+/- males 
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have enhanced T-TrkB activation only at the 30 minute time point, which appears to be due to 
increased phosphorylation (p-T-TrkB). Female BDNF+/- mice have attenuated T-TrkB activation at 
both 30 minutes and 24 hours, which is a combined effect of reduced phosphorylation with 
increased total T-TrkB levels. Taken together these data suggest that T-TrkB alterations are not 
directly correlated to BDNF levels due to the lack of genotypic difference in controls and the lack 
of pattern between reductions in BDNF and a corresponding change in the T-TrkB. Additionally, 
the alterations observed in T-TrkB seem to be an acute effect as a direct result of consumption 
due to the fact that changes were only observed at the 30 minute time point with the exception 
of female BDNF+/- mice. The T-TrkB receptor is hypothesized to inhibit the FL-TrkB receptor by 
binding with it to form an inactive receptor complex [70]. Although there may be support for 
this hypothesis here, further investigations would be required to confirm it. The levels of p-FL-
TrkB (normalized to actin) are attenuated 30 minutes after DID in the male WT mice; together 
with increases in total FL-TrkB, this change led to reduced activation. At the same time there 
were increases in total levels of T-TrkB. Similar trends were observed in female mice of both 
genotypes as well. It is logical to associate the reduction in activation of FL-TrkB to a direct result 
of the reduced BDNF levels, however it is possible that the changes in T-TrkB receptor levels are 
contributing to this attenuation. The important consideration though is that the function of T-
TrkB is dependent on its localization to the FL-TrkB receptor [69, 70]. Our work made no 
distinction in localization so further investigations would be required to elucidate what role, if 
any, the T-TrkB receptor is playing in the differences observed for the FL-TrkB activation 
following ethanol exposure. 
 
 
81 
 
 
4.5 Conclusions 
 The results of the investigation of BDNF-TrkB signaling in WT and BDNF+/- mice following 
7 days of DID are interesting and have set a foundation to continue to explore down the 
signaling pathways to determine molecular mechanisms. From Tables 1 - 4 it is clear that male 
WT mice undergo more alterations following DID compared to male BDNF+/- mice. Female WT 
mice undergo similar alterations to their male WT counterparts, while female BDNF+/- mice also 
undergo similar alterations to the male and female WT mice. Two opposing hypotheses were 
given above as to what the reductions in BDNF-TrkB signaling following DID could mean. One is 
that the BDNF neuroprotective role is significantly altered in the WT animals causing 
‘dependence’; the other is that the reduced BDNF-TrkB signaling is a positive in that it serves to 
limit synaptic plasticity following ethanol to reduce reinforcement. Despite the changes 
observed, there are many more questions generated by these data. Future directions include 
determining the mechanisms for increased TrkB receptor protein expression, what down-
regulations in BDNF-TrkB signaling mean for synaptic plasticity, and what alterations are 
occurring to BDNF and its receptor in other brain regions that input to the striatum. Also 
requiring further investigation are the signaling cascades downstream of TrkB and how gender 
may determine differences in the alterations following DID. Finally, the evidence that an 
“addicted” brain is created in the WT animals needs to be investigated further with behavioral 
studies to determine the phenotype of mice after 7 days of DID in order to better interpret what 
the molecular changes observed mean.  
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CHAPTER 5 
Characterization of the Nucleus Accumbens Dopamine System in Adenylyl 
Cyclase 1 & 8 Double Knockout Mice 
In collaboration with Dr. Alana Conti, Department of Neurosurgery, Wayne State University. 
5.1 Introduction 
 Adenylyl cyclase (AC) is an enzyme responsible for catalyzing the conversion of 
adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), an important second 
messenger involved in synaptic plasticity, learning, memory, and substance abuse, to name a 
few [10]. AC can be indirectly modulated by ethanol through its actions on other 
neurotransmitter systems [52]. Ethanol can also have direct action on AC signal transduction for 
which different AC isoforms show differential sensitivities [52]. Additionally, cAMP signaling has 
been implicated in regulating the stimulating and sedating properties of ethanol [78-80]. There 
are ten known ACs, eight of them activated primarily via sub-units of G-protein coupled 
receptors while the other two, AC1 and AC8, are stimulated by calcium via calmodulin signaling 
[10, 52, 80]. Mice lacking the AC1, AC8, or both isoforms have different sensitivities to the 
effects of ethanol [78-80]. Understanding how these molecular components respond to ethanol 
and cause these altered sensitivities will be important to the development of therapies in the 
treatment of alcohol use disorders. 
 Behaviorally, AC1 and AC8 double knock-out (DKO) mice exhibit differences in 
consumption and sensitivity to ethanol [80]. Using a two-bottle choice assay, Maas et al. 
observed that DKO mice consumed less ethanol than wild type (WT) littermates specifically at 
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higher concentrations of ethanol [80]. Additionally, they confirmed that these changes were not 
due to differences in caloric requirements or baseline taste differences [80]. In the same study 
using the loss of righting reflex (LORR) test, it was also observed that DKO animals were more 
sensitive to the sedative effects of ethanol [80]. The righting reflex refers to the animal’s reflex 
to correct the body’s orientation. In this test, the animal is laid on its back after sedation from a 
high dose of ethanol and the time required for the animal to regain consciousness and flip itself 
over is assessed. At higher doses of ethanol, DKO animals were sedated almost twice as long as 
the WT [80]. Using a lower dose of ethanol, it has been reported by Conti et al. that, while WT 
animals have increased locomotor activity following a 1 g/kg dose of ethanol, DKO animals show 
no change from baseline locomotor activity [79]. When a dose of 2 g/kg was given, DKO animals 
did show increased locomotor activity, however it was blunted compared to WT animals [79]. 
The same dose of 2 g/kg ethanol was also used by Mass et al. to study the ataxic effects of 
ethanol; in which DKO animals were not more sensitive [80]. These studies suggest that at the 
lower (2 g/kg) dose of ethanol, DKO and WT animals have different sensitivities to ethanol with 
relation to ethanol stimulation of locomotor movement, but motor coordination is not different 
[79, 80]. Together, these behavioral and consumption data illustrate that AC1 and AC8 play an 
important role in the physiological response to ethanol and that role differs depending on the 
ethanol dose. In this study, neurochemical investigations were carried out to identify potential 
mechanisms of AC1 and AC8’s modulation of ethanol sensitivities. 
Assessments of the role of AC1 and AC8 have elucidated a potential function for these 
isoforms in a homeostatic mechanism in response to ethanol exposure and neuronal inhibition 
[78, 80].  Ethanol exposure elicits phosphorylation of protein kinase A (PKA) targets. This 
phosphorylation has been compromised in DKO animals [80]. The AC1 and AC8 dependent 
changes in PKA phosphorylation are brain region dependent, suggesting that different brain 
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regions are responsible for the sedative versus ataxic response to ethanol and explaining why 
enhanced sensitivity is only observed with sedation [80]. AC1 and AC8 dependent cAMP/PKA 
signaling are important for regulating presynaptic activity through the modulation of exocytotic 
machinery [78]. Phosphoproteomic techniques used by Conti et al. have shown phosphorylation 
of several proteins involved in vesicular release after ethanol exposure in WT mice that was 
attenuated in DKO mice [78]. The reduced phosphorylation of these proteins would all 
contribute to a reduction in exocytotic release. These studies suggest that AC1 and AC8 are 
involved in a homeostatic response to the inhibitory effects of ethanol on neurotransmission.  
Given the aforementioned roles of ACs in mediating ethanol sensitivity as well as the 
role of cAMP in learning and memory, the goal of this study was to understand if there are also 
changes in the reward center of the brain in the DKO animals. The ventral striatum (recall from 
Chapter 1, Figure 1.2), also referred to as the Nucleus Accumbens (NAc), is the reward center of 
the brain, and is a dopamine (DA) rich region. Considering the established differences in 
sensitivity to ethanol, it is important to understand if these changes translate to the DA system 
of DKO animals, as well as how these changes may correlate with changes in behavior. Using the 
technique of microdialysis to investigate the NAc of these animals, initial experiments sought to 
determine if there were inherent differences in the DA system between the wild-type (WT) and 
DKO mice. Subsequent experiments served to probe differences in the presence of ethanol. 
Finally, an experiment to investigate stimulant drug response in DKO animals was also carried 
out based on unpublished locomotor activity experiments using methamphetamine (METH).  
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5.2 Methods 
The characterization of the DA response in DKO mice was performed using 
microdialysis. This method has been described in detail previously (Chapter 2, Section 2.4), thus 
this section will only highlight deviations from the previously described methods.  
5.2.1 Animals 
 WT and DKO animals were bred in Dr. Alana Conti’s lab (WT x WT and DKO x DKO); WT 
animals were originally purchased from The Jackson Laboratory (Bar Harbor, ME). DKO animals 
were offspring of homozygous mutants with a constitutive deletion of both AC1 and AC8. Mice 
were housed in groups of 4-5 with food and water available ad libitum. Animals were 
maintained on a 12 hour light/dark cycle (0600 lights on) and were between about 4-6 months 
of age. Animal care and use was in accordance with the National Institutes of Health Animal 
Care guidelines and approved by the Wayne State University Institutional Animal Care and Use 
Committee.  
5.2.2 Surgery 
 Investigation of the NAc of AC1&8 DKO animals was performed using microdialysis with 
sample analysis by HPLC coupled with electrochemical detection. Surgeries were performed as 
described earlier (Chapter 2, 2.4.2), although different coordinates were used to target the NAc. 
Initial coordinates from the Paxinos and Franklin mouse atlas were (ML +0.75, AP +1.50, DV -
3.75) [54]. After several surgeries and histological verification of probe placement, coordinates 
were optimized to (ML +0.70, AP +2.40, DV -3.60) for the mice used in this study (Figure 5.1). 
Additionally a smaller dialysis probe (1 mm in length, 240 µm diameter) was used for these 
experiments, due to the reduced size of the NAc compared to the caudate putamen (CPu) 
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(Figure 5.1). The brain slice in Figure 5.1 indicates the larger size of the CPu, and this region gets 
even larger moving to more posterior positions in the brain. 
(For more detailed methods used for histological verification please see Chapter 2, Section 2.5) 
 
Figure 5.1 A representative brain slice (150 µm) from a microdialysis animal, fixed in formalin 
and stained with cresyl violet. The green circle indicates the approximate region of the NAc and 
the dark purple line (green arrow) within that circle is where the probe was for this particular 
animal. Additionally the yellow circle is indicating the CPu as an illustration of the size difference 
between the two brain regions.  
 
5.2.3 Microdialysis 
In microdialysis the recovery of analytes is affected by the flow rate of the perfusate, 
with lower flow rates allowing for more analyte recovery [50]. The 1.1 µL/min flow rate 
traditionally used did provide suitable DA recovery with the smaller probe, thus the flow rate 
was reduced to 0.8 µL/min. As before, one hour of 20 minute baseline collections were taken 
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followed by i.p. administration of either ethanol (1 or 2 g/kg) or 5 mg/kg METH. Subsequent 20 
minute fractions collected for 1-3 hours after drug were then normalized to baseline values with 
baseline set at 100%. The zero net flux method was also used to determine ‘true’ extracellular 
DA levels (Chapter 2, Section 2.4.3, [50, 55, 56]). For this experiment, there were some changes 
made to the previous method due to the differences in brain region and experimental 
challenges with the smaller probe size required for the NAc. Recall that baseline samples were 
collected followed by perfusion of 3 different DA concentrations meant to bracket the 
concentration of extracellular levels. Previously each DA concentration was perfused for 1.5 
hours, however with the slower flow rate this did not provide enough time for the proper 
equilibration of the different concentrations of DA to be perfused through. Therefore, each 
concentration was perfused for one hour and forty minutes (6 fractions) so that each 
concentration of DA essentially had 2 equilibration samples collected and then 3 samples 
suitable for quantification. The concentrations of 5, 10 and 20 nM DA proved to be too high as 
they were all above the extracellular DA levels, so the concentrations were reduced to 2.5, 5, 
and 10 nM DA. Apart from the changes in perfusion times and DA concentrations used, the 
experiment was the same as previously described (Section 2.4.3). In vitro calibration was 
performed to determine the concentration of perfused DA (DAin). A plot was constructed of the 
difference of DAin and the recovered DA (DAout) from the animal, versus the DAin; the x-intercept 
of the linear regression of these points was indicative of the extracellular DA concentration 
DAext. The slope of the regression line was also used to analyze in vivo DA recovery and is 
referred to as the extraction fraction (Ed).  
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5.2.4 Sample Analysis 
Due to the reduced flow rate, only 16 µL of dialysate were collected for each sample. 
Analysis of a lower sample volume then required optimization of the HPLC method. Initially, a 
smaller 10 µL loop on the HPLC was used and overfilled. The DA signal was quite low with this 
method, so an alternative was to add 5 µL of a stabilizing solution, containing 0.2 M perchloric 
acid, 0.2 µM ascorbic acid, and 0.2 µM EDTA to the sample, bringing the total sample volume to 
21 µL, which could then be injected using a 20 µL sample loop [81]. The latter method was 
preferred based on the resultant improved intensity of the DA peak. Data analysis was 
completed as before using SPSS and the expectation maximization method to model missing 
values so that an appropriate repeated measures design could be used for statistical testing 
(chapter 2, section 8). The Greenhouse-Geisser correction was used in cases where sphericity 
was violated. 
5.3 Results 
5.3.1 Extracellular DA Levels in the NAc Determined by Quantitative Microdialysis Were Not 
Different for WT and DKO Mice 
Zero net flux microdialysis was used to determine if there were differences in basal DA 
levels in the NAc of DKO animals as compared to WT. From Figure 5.2A of the recovered DA 
(DAin – DAout) versus the DAin plot, it is apparent that the regression lines lie close to one 
another. In order to statistically compare the extracellular DA concentrations (DAext, x-intercept) 
and the slopes of the lines, bar graphs were generated for each (Figure 5.2B and 5.2C 
respectively). The average extracellular DA concentrations were 3.3 ± 1.6 nM for WT (n = 7) and 
2.8 ± 1.2 nM for DKO animals (n = 8), which were not statistically significant as determined by 
independent t-test (t(12) = 0.549, p = 0.593). The slopes of the curves provide in vivo DA 
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recovery and indicate DA turnover rate, which signify DA transporter function [50]. The slopes of 
the zero net flux curves for WT (0.28 ± 0.05) and DKO (0.28 ± 0.04) mice were not different 
(t(12) = 0.015, p = 0.988).  
Figure 5.2 Comparison of baseline DA levels and DA recovery in WT and DKO mice (n = 7-
8/group) using the method of zero net flux. A) Regression lines of DA recovered versus perfused 
DA in the zero net flux experiment. B) Summary of the x-intercept values which indicate 
extracellular DA concentrations and are not different for WT and DKO mice (p = 0.593). C) Slopes 
from lines in A, which are not different (p = 0.988). Data used to construct these plots can be 
found in Table A.11 of the appendix. 
 
5.3.2 Dose Dependent Differences in Response to Ethanol: DKO versus WT Controls 
 Mice were challenged with two different doses of ethanol, both of which are locomotor 
activating as evidenced by Conti et al. [79]. One hour of baseline collections (20 minute 
fractions) were completed before 1 g/kg ethanol was given systemically. DA levels were 
subsequently monitored for an additional 100 minutes following injection. One-way repeated 
measures ANOVA with the Greenhouse-Geisser correction showed no difference within-subjects 
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effect of time (p = 0.07), although DA levels do appear to be reduced 40 minutes after 1 g/kg 
ethanol challenge (Figure 5.3A). There was also no within-subjects interaction of time x 
genotype (p = 0.890), nor a between-subjects effect of genotype (p = 0.760).  Observations for 
the higher 2 g/kg dose of ethanol were quite different compared to the 1 g/kg dose. 
Approximately 20 minutes after the 2 g/kg ethanol challenge, DA levels in WT mice increased to 
about 50% greater than baseline whereas the DKO animals, similar to the 1 g/kg dose 
experiment, showed no difference in DA levels. Interestingly, in DKO animals approximately 80 
minutes after ethanol injection a slight reduction in DA levels was observed (Figure 5.3). There 
was no within-subjects effect of time (p = 0.161) observed for the 2 g/kg ethanol challenge and 
no interaction of time x genotype (p = 0.093). There was however a significant between-subjects 
effect of genotype (F(1, 12) = 6.24, p < 0.05), demonstrating that the genotypes responded 
differently to ethanol.  
 
Figure 5.3 DA response to ethanol challenge reported as percent of baseline (n = 5-7 / group) A) 
After 1 g/kg ethanol challenge was not different genotypically different (p = 0.161). B) Percent of 
DA levels after 2 g/kg ethanol challenge, where there was an increase in percent DA in WT 
animals, while there was no difference in DKO animals (*, p < 0.05). Data used to make these 
plots is outlined in Table A.12 of the appendix. 
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5.3.3 DKO and WT Show Similar Stimulation Profiles Following a Systemic 5 mg/kg Dose of 
METH 
 Unpublished observations personally communicated from Dr. Alana Conti’s lab reveal 
that DKO animals have been observed to have lower METH-stimulated locomotor activity 
compared to their WT counterparts. Given these differences and that striatal DA 
neurotransmission is important in motor behavior the DA response to a 5 mg/kg METH i.p. 
challenge was assessed in the NAc of these mice. The baseline normalized DA response to METH 
over time in WT and DKO mice appear to be similar (Figure 5.4A). Repeated measures one-way 
ANOVA with the Greenhouse-Geisser correction showed a significant within-subjects effect of 
time (F(1.36, 18.967) = 18.49, p < 0.001) but no interaction of genotype x time (p = 0.598). There 
was also no between-subjects effect of genotype observed (p = 0.560). Analyzing the data and 
the curves, it appears that the extracellular DA levels in DKO animals do not return to baseline 
as they do in WT animals. From 240 – 300 minutes of collection time, the DA levels of DKOs 
remain slightly elevated. Due to this observation, an area under the curve analysis of the 
baseline-corrected data was done and summarized as a bar graph (Figure 5.4B). DKO animals 
appear to exhibit a larger average area under the curve (230000 ± 53000 arbitrary units) 
compared to WT littermates (140000 ± 37000 arbitrary units); however, due to large SEMs, this 
trend is not statistically significant (p = 0.188). 
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Figure 5.4 DA response to a locomotor activating dose of 5 mg/kg METH reported as percent of 
baseline (n = 8/group). A) Time course of percent DA changes following METH; results were not 
different between genotypes (p = 0.560). B) Summary of area under the curve analysis with 
plots from A where DKOs have a higher average AUC; this average is not statistically significant 
(p = 0.188). Data to construct these plots can be found in Table A.13 of the appendix. 
 
5.4 Discussion 
5.4.1 DKO Animals Display Normal DA Function in the NAc 
 Before investigating the effect of ethanol on the NAc DA system in DKO animals, it was 
important to first understand if there were any differences in their naïve DA system. The 
quantitative microdialysis method of zero net flux showed that DKO mice have similar 
extracellular DA levels as WT littermates. Additionally, characterization of stimulated DA release 
and investigation of transporter function carried out using the technique of fast scan cyclic 
voltammetry in brain slices from DKO and WT mice showed no genotypic differences (personal 
communication with Dr. Madiha Khalid). DA neurotransmission is important in mediating 
movement and previous work has shown that DKO animals are more active in baseline 
locomotor activity than their WT littermates [79]. Although presynaptic DA activity does not 
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always translate directly to locomotor behavior, one may expect to see some changes in DA 
given the observed behavioral differences. Microdialysis experiments only provide presynaptic 
information therefore the behavioral changes observed despite the apparently normal 
functioning DA system suggest that there are changes downstream from DA responsible for 
those locomotor alterations.    
5.4.2 Dose Dependent and Genotypic Differences Observed in the NAc DA System in Response 
to Ethanol Challenge 
 At the lower-dose of ethanol administered (1 g/kg), the DA system of WT and DKO 
animals responded similarly, with no difference in DA levels compared to baseline. However at 
the higher dose of ethanol (2 g/kg) genotypic differences were observed. Normally a dose of 2 
g/kg ethanol elicits an increase in DA in the striatum [34, 35], which was also observed in our 
study with WT, mice but not with DKO mice. In a study by Conti et al., locomotor behavior was 
monitored following an ethanol challenge of the same dose (2 g/kg) where DKO mice did exhibit 
increased activity following ethanol but it was blunted compared to WT mice [79]. The 
differences in ethanol induced locomotor output are likely due to combined effects of 
alterations in other systems in the DKO animals and the observed difference in pre-synaptic DA 
release.  
Taking what is known about the proposed role of the AC1 and AC8 in a homeostatic 
response to ethanol, the alterations in phosphorylation after ethanol that have been observed 
in the cortex could be important in mediating these different DA responses. After ethanol 
exposure phosphorylation of several exocytotic proteins is increased in the cortex to promote 
neuronal activity and this cortical phosphorylation is reduced in DKOs [78]. The circuitry 
connecting the NAc and the cortex involve the excitatory amino acid glutamate neurons (see 
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Figure 1.5) which can stimulate DA neurotransmission. The inhibition of glutamate neurons in 
the cortex of DKO animals (decreased phosphorylation) could prevent ethanol from stimulating 
the DA release in the NAc, which is observed in WT animals. These hypotheses would need 
further investigation due to the fact there is limited knowledge on the DA system of the DKO 
mice and the fact that the investigations of molecular changes in DKOs were carried out using a 
dose of ethanol that is much higher (4 g/kg) [78, 80].  Additionally, reports of AC expression and 
activity in the striatum are scarce and do not discriminate between pre- or post-synaptic 
localization [82, 83]. There is potential for a more direct relationship between AC1 and AC8 in 
the mediation of the presynaptic DA terminals response to ethanol being analyzed here. The 
blunted phosphorylation of exocytotic machinery discussed earlier could be also be occurring in 
the NAc in response to ethanol, which would explain the lack of DA release in the DKO animals.  
5.4.3 DAergic METH-Stimulation is Similar in WT and DKO Animals.   
 Investigation of AC1 and AC8 in the literature has primarily focused on their roles in 
response to ethanol exposure due to the enhanced sensitivity to sedating doses of ethanol [78, 
80]. There is also potential that these isoforms of AC are important in mediating effects of other 
substances of abuse, such as psychostimulants (like cocaine or amphetamines). Additionally, 
cAMP second messenger signaling pathways are important in long-term memory formation, 
which has implications in the propagation of addiction [83]. DiRocco et al. investigated the role 
of AC1 and AC8 in cocaine-sensitization using single knockout animals of each isoform, and DKO 
animals [83]. Acute administration of cocaine produced increased locomotor activation in DKO 
animals over their WT counterparts [83]. Acute cocaine also produced enhanced PKA 
phosphorylation in the striatum of WT but not DKO animals [83]. Further experiments suggested 
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that these AC isoforms are important for ERK activation, which leads to long-term 
neuroadaptations [83].  
The characterization of DKO animals in response to METH has provided information 
opposite to that observed with cocaine. DKO animals have a blunted locomotor stimulation 
compared to WT littermates when METH is administered acutely (personal communication with 
Dr. Conti). METH and cocaine both produce large extracellular concentrations of DA through 
slightly different actions involving the DA transporter; it is interesting that there is decreased 
locomotor activity in DKOs with one drug (METH) and increased activity with the other 
(cocaine), compared to WT mice. Cocaine blocks the DA transporter, leading to an increase in 
extracellular DA levels since the DA transporter is the primary clearance method for DA [5]. 
METH acts as a DA transporter substrate, vesicular monoamine transporter (VMAT) substrate, 
monoamine oxidase (MAO) inhibitor, and tyrosine hydroxylase (TH) activator, all of which lead 
to large amounts of DA in the synapse as well [5]. Given the similar pre-synaptic action of METH 
and cocaine to robustly stimulate DA, the opposing observations for the two drugs would 
suggest complex molecular interactions for AC1 and AC8 to regulate the behavioral responses 
differently. 
In order to understand the differences in locomotor stimulation following acute METH, 
microdialysis was used to determine if there were differences in DA release in DKO animals. 
About 40 minutes after METH (5 mg/kg) injection, DA levels in WT and DKO animals were 
increased to a peak of about 2800% over baseline, with no difference between genotypes. The 
probe placement of these animals was analyzed in order to confirm that METH response 
variability was not a result of regional differences. The majority of probes were located in both 
of the NAc subregions of the core and shell together (Figure 5.5). Several of the higher 
96 
 
 
responding mice had their probes more posterior (Figure 5.5, bregma 1.10mm) than others 
however they were still in the NAc so they were not excluded. The similar DA release in WT and 
DKO mice following METH, with a difference in locomotor activation, indicates that there are 
downstream (possibly post-synaptic) alterations that change the behavioral response to METH 
in these animals. The inconsistencies with the similar pre-synaptic acting drugs cocaine and 
METH to produce large extracellular concentrations of DA, supports the importance of the cAMP 
second messenger signaling and the multitude of downstream systems it can act on. As 
mentioned in the DiRocco et al. paper, in which they examined one particular downstream 
pathway of AC1 and AC8 and noticed alterations. It is likely that despite the two drugs’ similar 
pre-synaptic result on DA, their behavioral response is mediated in different ways by 
downstream effects of AC1 and AC8 promoted cAMP signaling [83].   
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Figure 5.5 Adapted brain atlas images showing the microdialysis probe placement for mice that 
were given METH injections, with WT mice indicated in black and DKO mice in orange [54]. Slices 
vary in their anterior/posterior distance from bregma as indicated in the upper right-hand 
corner of each brain. 
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5.5 Conclusions 
 Analysis of the DA system using microdialysis is advantageous in that measurements are 
strictly pre-synaptic in the brain region of interest and they occur in an intact in vivo system 
which can simplify interpretations. Challenges arise when comparing microdialysis data to 
behavioral data and tissue studies, where post and pre-synaptic alterations aren’t always 
distinguished. The DA system of DKO animals on a basal level (with no drug) appears to function 
normally, evidenced in the zero net flux and fast scan cyclic voltammetry studies. In experiments 
assessing pre-synaptic DA release, DKO animals were only affected differently from WT mice by 
the 2 g/kg dose of ethanol. Genotypic differences were not observed for the 1 g/kg ethanol dose 
(DA levels did not change after ethanol for both genotypes) or 5 mg/kg METH (both genotypes 
had similar increases in DA). In all conditions (no drug, ethanol, or METH) assessed, differences 
have been observed in DKO animals’ behavioral response determined by locomotor activity 
(personal communication with Dr. Conti, [79]). The inconsistencies in DA response and 
locomotor behavior suggest important roles for these AC isoforms (1 and 8) post-synaptically 
and downstream from the DA nerve terminals of the NAc. The studies of downstream 
phosphorylation targets of cAMP signaling carried out in DKO animals with cocaine and ethanol 
support the post-synaptic role of cAMP signaling [78, 83], essentially showing that the AC1 and 
AC8 isoforms are crucial to the behavioral responses to these drugs and that seemingly different 
cAMP pathways are activated depending on the drug. Therefore, to fully understand the AC1 
and AC8 roles, detailed molecular studies need to be carried out in relation to each specific 
drug. Finally, it would also be useful to determine a point in cAMP signaling that is important for 
mediating the different behavioral responses for the stimulants cocaine and METH, which both 
cause increased extracellular DA levels but with different behavioral outputs.  
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CHAPTER 6 
Conclusions and Future Directions 
 The different investigations herein share the common overarching goal of 
understanding the effects of ethanol on the brain in order to aid in the development of 
therapies for those individuals struggling with alcohol use disorders. The complexity of 
understanding ethanol’s action on the brain is indeed great, given the vast number of neural 
networks it acts on to produce neural adaptations [52]. Further complicating the ability to 
understand ethanol is the confounding factors of genetic and environmental influences that are 
associated with alcohol abuse and dependence.  
6.1 Relating BDNF-TrkB Signaling Measures to Microdialysis Characterization of Ethanol 
Stimulation 
 Examining only male WT mice, recall that 24 hours after 7 days of DID, reduced BDNF-
TrkB signaling (represented in Figure 6.1) was observed. An ethanol challenge administered at a 
corresponding time, showed that there was no longer an increase in DA levels, as previously 
observed under naïve conditions. Together, the reduced BDNF-TrkB signaling and DA tolerance 
to ethanol could suggest that reduced BDNF levels may indicate a reduction of input from the 
excitatory glutamatergic neurons of the cortex to the striatum and that this absence renders 
ethanol unable to elicit DA release. However, this hypothesis is challenged however when 
considering BDNF+/- mice, since they also show a similar tolerance to ethanol stimulation of DA 
without reduced BDNF-TrkB function after DID (compared to naïve BDNF+/-). Taken together, 
findings from the BDNF-TrkB signaling and ethanol challenge experiments, summarized in Figure 
6.1, would suggest that BDNF-TrkB alterations following repeated ethanol exposure are either 
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not responsible for the loss of ethanol-induced stimulation of DA or the downstream signaling of 
BDNFs action through TrkB is processed differently in the two genotypes.  
 
Figure 6.1 Seven day DID drinking data with a summary of the neurochemical measures made 
prior to and after DID exposure. Day 0 represents observations in naïve animals from the current 
study and previous findings with WT shown in blue and BNDF+/- mice in green [29]. The 
notations of increases, decreases, or equal levels are compared to control levels for non-treated 
mice of the same genotype.  
 
6.2 Consideration of the DID Model 
Acute reductions in BDNF levels have been observed 45 minutes after 2 g/kg systemic 
ethanol challenge, in both WT and BDNF+/- mice [29]. Together, the acute observations (from 
previous studies) and the reduced BDNF levels observed here in WT animals after repeated 
ethanol exposure, an initial hypothesis is that after the initial DID session BDNF levels are 
reduced in WT animals and the reduction persists over the course of the 7 days of DID. BDNF 
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levels in BDNF+/- mice are probably reduced after the initial DID session (based on an acute study 
by Bosse et al., [29]), but at some point during the 7 days of DID they appear to be compensated 
for and return to naive BDNF+/- mice levels. The reduction in BDNF-TrkB signaling in the WT 
animals could be responsible for the increase in consumption observed from day 1 to day 7. 
However, when considering BDNF+/- animals, it is interesting to note that they also increase 
ethanol consumption from day 1 to day 7, but without further reduction in BDNF-TrkB signaling. 
There is seemingly conflicting data between WT and BDNF+/- mice, where consumption is similar 
at day 7, but BDNF-TrkB signaling is attenuated in WT mice only (as compared to their own 
controls). It is possibile that the drinking model used is producing an addictive/dependent 
phenotype in the WT mice. If the BDNF neuroprotective pathway has been disrupted, then the 
WT brains could be more representative of an ethanol dependent brain. The reduced BDNF-TrkB 
levels in WT with enhanced consumption would further support the importance of BDNF’s 
protective role in the onset of alcohol dependence. However, if 7 days of DID is creating this 
phenotype in WT mice, then we are comparing the BDNF+/- mice to a control group that we have 
caused dysfunction in, making this model less suited for our determination of the effect of low 
endogenous BDNF levels on susceptibility to alcohol dependence.  
The potential recovery of BDNF to baseline levels (in reference to the genotype) over 
repeated exposures could also be interpreted as evidence of enhanced ethanol preference in 
our model which has been observed previously [26, 28]. The ability of BDNF levels to return to 
control levels in BDNF+/- mice during continued ethanol exposure may point to increased 
synaptic plasticity promoting ethanol reinforcement, as compared to WT mice who have 
attenuated BDNF-TrkB signaling after 7 days of DID. If the binge consumption is in fact causing 
deterioration of the BDNF homeostatic mechanism in WT mice, than exposure past 7 days could 
lead to a point where BDNF levels return to control while still having enhanced consumption, 
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similar to the observations in the BDNF+/- mice (Figure 6.2). If this deterioration of the BDN 
homeostatic mechanism were true, then it would suggest that changes in BDNF-TrkB signaling 
observed in both genotypes are indicative of addiction/dependence formation caused by the 
DID model. The restoration of BDNF-TrkB signaling to control during continued exposure to 
ethanol could be an important indicator that dependence forming neuroadaptations have 
occurred. It is possible that this dependence occurs very quickly in the BDNF+/- mice, and since 
no measurements were made earlier than 7 days we did not observe this. This hypothesis could 
be tested in the future by taking similar measures at an intermediate time point during the 7 
days of DID and by extending the length of exposure to see if BDNF levels return to normal with 
continued exposure in WT mice; a suggested scheme is diagrammed in Figure 6.2. If this 
hypothesis is true, then expected outcome would be to that BDNF levels in WT mice would 
return  to control levels even with repeated ethanol exposure, similar to the BDNF+/- mice 
(Figure 6.2). Furthermore, if we define our criteria for dependence as having normal BDNF and 
TrkB levels with continued ethanol exposure, it would be of value to test how long after ethanol 
cessation a single re-exposure to ethanol could again reduce BDNF levels. The length of 
cessation before BDNF levels can be reduced again could be interesting given the implications of 
BDNF’s role in relapse [84]. A potential outcome for the cessation experiments (proposed in 
Figure 6.2) would be that after several days, re-exposure using DID would have WT mice 
essentially starting over as naïve animals, while BDNF+/- mice still experience enhanced 
consumption and no changes in BDNF after ethanol exposure. Preliminary data (n =1/genotype, 
Figure 6.3) collected for the development of a relapse drinking model, where a BDNF+/- mouse 
have enhanced consumption when ethanol was reinstated after 3 days off from DID. No 
concrete conclusions can be made from this observation due to the single n-value but the 
difference does warrant additional investigation. Furthermore, continued reinstatement may 
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indicate that the hypothesized return to normal function of BDNF-signaling (normal levels of 
BDNF and TrkB without ethanol) in WT animals is disrupted again, given the increase across the 
4 days of re-exposure (Figure 6.3B).  
 
Figure 6.2 A schematic of proposed alterations to BDNF levels during different time points of 
DID exposure and after reinstatement following several days of no drinking. Representations of 
BDNF levels are in reference to control levels for the genotype, with the blue indicating WT 
changes and the green depicting BDNF+/- changes.  
104 
 
 
 
Figure 6.3. Pilot results of drinking data over 7 days (g/kg) followed by 3 days with no exposure 
(red x’s) and initial reinstatement on day 11 followed by 3 subsequent DID sessions (n = 1 / 
group).  Data for this experiment can be found in Table A.14 of the appendix. 
 
6.3 Adenylyl Cyclase Involvement in DID Induced Tolerance to Ethanol Stimulation 
 Investigations using adenylyl cyclase 1 and 8 (AC1 & AC8) double knock-out (DKO) 
animals clearly illustrated the importance of AC1 and AC8 in ethanol stimulation of DA release 
(Chapter 5, Figure 5.3). While there are several possible explanations for the lack of DA response 
to ethanol after 7 days of DID in WT and BDNF+/- mice, the evidence of the roles of AC1 and AC8 
in ethanol stimulated DA release makes AC an attractive target. The DKO studies were carried 
out in the NAc and therefore, to test this hypothesis, trends would need verification in the CPu. 
In addition it would also be interesting to assess the AC activity in the CPu of WT and BDNF+/- DID 
mice and see if there is a significant loss of AC function, which could explain the inability of 
ethanol to release DA after 7 days of DID (Chapter 3, Figure 3.2). Although it was previously 
suggested that BDNF-TrkB signaling was not involved in the observed ethanol tolerance, it could 
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in fact be mediating reduced AC1 & 8 activity via regulation of gene-transcription. However, the 
caveat of BDNF+/- mice having ‘normal’ BDNF-TrkB signaling and DA tolerance remains. If BDNF-
signaling is responsible for alterations in AC function following DID through altered transcription 
of molecules that target AC, then this would suggest that BDNF-TrkB signaling may function 
differently in BDNF+/- mice compared to WT mice, something that has yet to be assessed in this 
mouse model. Alternatively, there may be inherent differences in AC1 & 8 function in WT and 
BDNF+/- mice. Previous experiments using microdialysis to assess ethanol-stimulated DA release 
in these mice showed blunted release in BDNF+/- mice as compared to WT [29]. This divergence 
was not observed in our study, potentially due to diurnal variation; it is postulated that the 
decreased neuronal tone during the dark cycle masked this genotypic difference [61, 62]. If AC1 
& 8 function is reduced in BDNF+/- mice, then it may be that, despite BDNF-signaling restoration 
by the 7th day of DID, AC function is not restored.   
6.4 One Day DID Illustrates the Importance of Assessing Other Time Points Besides 7 days of 
DID  
For the DID studies, the duration of ethanol exposure was 7 days, followed by 
microdialysis or tissue studies. Following the weeklong consumption, there were several 
interesting neuroadaptations observed, such as DA tolerance or reduced BDNF-TrkB signaling. 
However the time frame in which these striatal changes occur and whether or not they persist is 
unknown. It is also unknown whether these neuronal changes occurred after 1 day and 
remained consistent over the course of the exposure or if a gradual transition to these 
alterations occurred instead. Also, many of the striatal neuroadaptations were observed 24 
hours after the last ethanol exposure, which leaves us asking how long before they return to 
normal, if ever. The importance of assessing at least one intermediate time point is evidenced 
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by preliminary microdialysis data that were collected 24 hours after one DID session in WT and 
BDNF+/- mice to assess their DA levels following an ethanol challenge (Figure 6.40). WT and 
BDNF+/- mice show similar responses to a 2 g/kg ethanol challenge under control or 7 day DID 
conditions, however the responses after only one drinking session are vastly different: BDNF+/- 
mice (Figure 6.4A) show attenuation in DA levels whereas WT mice (Figure 6.4B) show no 
difference (both compared to the response in control animals). Considering the aforementioned 
hypothesis that the BDNF+/- and WT mice undergo similar alterations with the DID procedure but 
that changes occur more rapidly in the BDNF+/- mice, this latest observation would be interesting 
to investigate further. Similarly if there is a role for AC in mediating the DA tolerance to ethanol 
stimulation, the tolerance at 1 day of DID in BDNF+/- mice could indicate that they have lower AC 
function and are more susceptible to alterations following ethanol exposure. Although these 
data were collected for only 2 mice for each genotype, it does highlight the importance of 
looking at other time points prior to the full 7 day exposure.    
 
Figure 6.4 Dopamine response to a 2g/kg ethanol challenge in naïve and 7 day DID mice as 
previously reported (Chapter 3, Figure 3.2), with the addition of 1 day DID mice (n=2) for both A) 
BDNF+/- and B) WT mice. Data for the 1 day DID experiment can be found in Table A.15 of 
appendix. 
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6.5 General conclusions 
 Considering the discussion above regarding the BDNF+/- and DKO animals, several 
mechanistic proposals for further investigation can be suggested with regard to DA tolerance to 
ethanol-stimulation, the ramifications of altered BDNF levels and TrkB activation, and potential 
evidence of the DID model promoting an ethanol dependent animal. It is hypothesized that the 
DID model is producing an ethanol dependent animal in both WT and BDNF+/- mice, with the 
latter being affected much earlier in treatment. It is thought that initially, ethanol consumption 
causes attenuations in BDNF that lead to increased consumption in both genotypes and a 
potentially long-lasting reduction in function of AC1 & 8 in the BDNF+/- mice. Eventually, over the 
course of repeated exposure, the BDNF-signaling for BDNF+/- mice returns to normal for the 
genotype, but it is hypothesized that AC function is still reduced based on the continued 
tolerance to ethanol induced stimulation of DA. In the WT animals BDNF-signaling continues to 
be reduced with repeated exposure eventually leading to a hypothesized attenuation in AC 
activity similar to the BDNF+/- mice. The hypothesized decreases of AC1 & 8 are plausible given 
the DA tolerance to ethanol stimulation after 7 days DID and the divergence in response after 1 
day of DID between the two genotypes. Finally, the alterations in BDNF-TrkB signaling in WT 
mice, with further investigation, could provide evidence that the DID model produces rapid 
induction of a dependent phenotype. Furthermore, the recovery of BDNF-TrkB signaling in the 
BDNF+/- animals should be investigated in terms of the long-term ramifications and what this 
recovery means behaviorally.   
The findings presented here illustrate that there is still more to be understood about 
how different neural networks process and respond to ethanol and, conversely, how different 
exposure amounts and lengths are able to cause varying alterations in the brain. Continued 
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investigations into how alcohol is changing the brain and how different exposure methods have 
different effects will be important in understanding the human condition. No two alcoholics 
become addicted in the same fashion, nor did they have the same drinking patterns, as such 
there is no best practice for the animal models used to study alcohol abuse. Developments of 
models that better capture the human condition are strived for and for each new model 
developed, there is potential for different neuronal adaptations to be observed.  
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APPENDIX 
This appendix provides the raw data used to make the plots throughout the dissertation and the 
blots used to make the histograms in Chapter 4. 
Table A.1 Daily ethanol consumption (g/kg) for WT and BDNF+/- mice used in the first DID study 
described in Chapter 3. These data were used to create the graphs in Figure 3.1. 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Genotype 
1.73 2.23 2.30 2.17 2.39 3.06 2.76 
WT 
3.05 2.17 3.78 3.48 3.53 2.74 3.43 
3.52 3.30 2.90 4.48 3.44 3.82 4.37 
2.07 3.13 2.28 3.20 2.62 2.27 3.67 
2.34 1.19 2.72 3.08 3.59 2.01 3.69 
1.61 2.88 2.33 2.09 2.53 2.82 2.65 
2.00 1.92 2.52 3.40 3.38 3.81 2.80 
2.41 2.08 2.70 3.26 2.64 3.37 3.00 
2.59 3.59 2.41 1.91 2.95 2.24 3.77 
0.63 2.87 4.03 3.93 4.47 2.77 4.34 
2.40 3.08 3.11 3.94 4.14 3.08 5.17 
2.46 3.02 1.96 4.11 2.55 3.53 2.84 
1.35 5.85 2.51 0.98 1.94 1.62 2.11 
1.80 3.02 3.09 2.55 3.11 3.15 3.19 
BDNF+/- 
2.57 3.40 3.29 2.89 2.68 2.30 3.83 
1.67 2.50 2.61 3.43 4.00 3.15 3.45 
3.17 4.43 3.37 2.30 2.92 2.28 3.80 
1.89 2.22 2.36 2.11 3.42 1.95 2.15 
2.44 3.46 2.66 3.45 3.64 3.28 2.58 
1.85 2.76 3.23 3.83 3.99 3.30 3.35 
3.22 2.32 2.95 3.21 2.99 2.23 2.77 
2.07 1.81 2.81 3.65 3.12 3.24 4.35 
2.05 2.96 3.36 4.36 3.79 3.34 3.62 
2.48 3.41 3.61 4.15 4.10 3.94 2.72 
2.17 4.47 3.32 4.15 4.02 2.32 2.20 
2.26 1.74 1.00 2.04 1.65 2.46 2.14 
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Table A.2 Uncorrected DA levels (in nM) over time used to create the baseline normalized plots 
from the ethanol challenge experiments in Figure 3.2 of Chapter 3 for WT and BDNF+/- mice. 
20 min 40 min 60 min 80 min 100 min 120 min 140 min 160 min 180 min 
Group 
 
2.1 2.9 3.3 3.3 3.6 2.5 2.8 2.9 2.8 
WT 
Control 
 
3.4 2.9 2.1 2.2 1.9 1.9 2.0 2.0 
1.1 1.1 0.9 0.8 1.6 1.3 1.2 1.0 0.7 
1.1 1.9 1.7 1.8 1.7 2.1 2.3 2.4 2.5 
 
0.7 0.6 0.4 0.3 0.3 
 
0.8 0.6 
4.8 3.9 3.8 4.4 4.4 5.2 5.6 4.2 
 
4.8 4.2 4.7 4.7 5.8 6.0 5.5 5.2 5.1 
4.2 4.5 3.9 4.4 4.4 4.5 4.8 5.0 5.6 
3.0 3.1 3.4 3.4 3.7 3.3 3.4 3.2 3.8 
4.9 5.0 5.2 5.8 6.2 6.0 5.5 5.3 5.7 
4.7 4.7 3.2 3.3 4.0 3.8 4.3 4.3 4.2 
 
0.4 0.8 1.0 
 
1.0 0.7 0.7 0.3 
0.4 
 
0.4 0.5 0.4 0.8 0.8 0.4 0.3 
2.6 2.5 2.4 2.8 3.8 4.0 3.9 3.5 3.1 
0.7 0.2 0.5 0.3 0.3 0.3 0.4 0.3 
 
WT 
DID 
1.1 1.1 
 
1.2 1.1 1.0 1.3 1.0 
 
2.3 3.7 
 
2.5 1.7 1.6 1.8 3.2 1.5 
3.1 3.0 2.8 2.9 
 
2.9 3.2 2.8 2.7 
1.7 1.2 1.4 1.2 1.3 1.5 1.2 1.4 1.1 
1.5 1.3 1.5 1.6 1.3 1.4 1.4 1.4 1.3 
1.4 1.4 1.2 
 
1.5 1.4 1.4 1.3 1.5 
 
4.4 4.7 4.9 5.0 5.3 5.3 5.0 4.6 
BDNF+/- 
Control 
2.3 2.1 2.4 4.7 3.9 4.8 6.2 3.2 3.0 
3.5 3.8 4.0 4.2 2.2 2.6 2.1 2.5 2.3 
2.4 2.8 2.2 2.5 2.4 2.7 2.6 2.7 2.8 
3.4 3.1 2.8 2.9 3.9 3.2 2.8 3.0 3.1 
4.7 6.2 5.5 4.4 4.4 5.9 4.6 4.4 5.3 
1.9 1.9 1.9 2.5 1.9 2.0 1.9 1.8 1.7 
 
0.7 0.2 0.5 0.8 
 
0.2 0.3 1.0 
4.3 4.6 4.9 4.9 5.7 5.7 5.4 4.8 5.3 
3.8 3.8 4.0 4.2 4.5 4.5 4.0 3.9 4.3 
 
1.7 2.0 1.3 1.8 1.3 1.6 1.3 1.3 
1.2 
 
2.2 2.4 1.9 2.5 2.0 2.9 1.7 
BDNF+/- 
DID 
4.4 6.0 4.3 4.4 5.1 5.0 5.9 4.9 4.6 
15.7 8.0 6.6 9.7 
 
9.8 13.5 10.5 9.6 
1.3 1.4 1.0 0.9 1.0 0.9 1.0 1.0 
 
2.5 2.8 2.7 2.8 2.4 2.8 3.1 2.6 2.4 
2.4 2.5 2.7 2.4 
 
2.7 2.7 2.3 2.1 
 
3.9 3.0 2.1 1.6 1.5 1.5 1.2 1.7 
2.0 2.5 
  
2.1 1.8 1.9 1.7 1.7 
1.2 1.6 1.2 1.3 
 
1.1 1.5 1.2 1.8 
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Table A.3 Uncorrected DA levels (in nM) over time used to create the baseline normalized plots 
from the 3 mg/kg METH challenge experiments in Figure 3.3 of Chapter 3 for WT and BDNF+/- 
mice. 
20 
min 
40 
min 
60 
min 
80 
min 
100 
min 
120 
min 
140 
min 
160 
min 
180 
min 
200 
min 
220 
min 
240 
min 
Group 
4.6 4.4 4.7 31.9 38.7 37.0 31.0 24.9 19.8 16.3 
  
WT 
Control 
1.9 1.9 1.5 
 
2.8 2.0 2.2 1.6 1.3 
 
1.1 2.5 
1.6 1.3 1.3 
 
5.0 4.5 3.3 2.1 1.9 2.2 1.9 1.9 
0.4 0.6 0.6 
 
7.8 5.3 2.8 2.1 0.6 
   
1.9 1.7 1.1 9.7 19.4 
 
16.9 11.0 11.7 8.7 6.0 3.9 
1.2 1.4 1.2 10.5 27.1 7.9 4.1 2.3 1.6 0.2 0.2 0.1 
1.7 1.7 1.6 12.5 15.6 12.8 11.7 8.1 7.3 5.5 3.6 2.9 
1.0 1.3 
 
15.3 29.8 24.1 16.9 12.8 11.5 10.4 8.9 7.1 
1.4 0.9 
 
14.8 
 
22.1 16.7 10.4 8.4 10.7 5.7 6.6 
0.4 1.1 1.2 
 
17.2 10.7 
 
5.6 5.4 4.3 3.1 2.0 
 
0.7 0.5 3.7 30.3 24.5 19.9 11.5 11.6 7.1 6.7 5.3 
1.4 2.4 1.0 20.5 27.6 24.0 19.8 15.9 12.9 9.8 5.9 3.7 
3.5 3.7 3.3 12.1 21.1 13.5 10.0 5.8 6.6 5.3 4.6 4.1 
4.1 2.2 1.6 32.0 36.2 33.5 26.2 15.8 9.3 12.2 7.9 6.4 
WT 
DID 
 
1.2 3.3 17.2 36.6 30.9 32.7 19.6 15.1 12.4 12.0 10.7 
1.7 3.2 2.7 29.1 54.8 37.6 31.0 23.7 12.2 
  
4.9 
1.4 1.0 
 
5.3 17.0 12.2 9.4 8.2 7.3 7.0 4.8 4.7 
1.5 1.1 1.0 19.4 42.0 38.2 33.4 22.4 20.6 17.5 19.7 13.2 
3.7 2.8 2.7 6.3 15.0 10.2 8.7 6.9 6.0 4.6 3.2 2.8 
2.4 2.4 2.4 17.8 19.8 13.5 12.2 9.7 6.7 5.9 4.5 3.5 
BDNF+/- 
Control 
2.7 2.0 0.7 58.9 88.4 60.6 38.3 40.5 28.4 10.7 21.2 18.0 
0.8 
 
1.3 0.6 2.5 3.6 5.0 2.4 2.3 1.3 1.0 1.1 
0.3 1.0 0.8 3.8 3.8 4.3 3.1 3.0 1.7 1.2 1.3 0.9 
4.4 3.3 3.6 10.0 11.4 11.4 9.8 9.2 7.0 7.1 7.8 7.3 
4.3 4.6 2.4 11.8 21.2 18.2 11.8 10.6 9.4 9.0 9.2 6.8 
3.0 3.1 2.2 
 
19.8 10.7 10.2 9.7 6.8 2.9 3.2 2.1 
1.6 1.6 2.0 10.7 17.4 17.6 15.7 11.8 9.2 7.8 5.8 4.3 
BDNF+/-  
DID 
12.6 11.1 10.5 16.6 20.1 16.4 15.7 14.4 11.8 9.8 9.5 9.4 
1.4 1.2 1.1 5.3 9.9 7.3 5.0 3.8 2.7 2.2 1.3 1.4 
3.7 3.7 3.6 
 
65.7 48.3 28.5 24.3 16.2 12.3 9.2 8.1 
2.3 2.3 2.2 20.1 36.3 25.6 23.6 18.5 15.8 11.8 9.3 7.6 
2.1 2.5 2.3 23.4 56.3 48.7 43.3 36.1 28.2 25.0 23.6 18.8 
0.4 0.3 0.3 4.3 5.9 4.6 3.8 3.6 2.8 1.8 1.4 1.3 
15.1 15.5 13.0 17.8 28.0 24.6 28.6 25.0 18.6 16.3 13.5 10.8 
0.8 1.2 1.2 3.6 3.8 3.1 2.5 
  
1.4 0.6 
 
4.2 2.3 0.9 8.3 15.0 8.9 6.4 4.4 3.0 3.5 2.5 2.7 
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Table A.4 DA levels (in nM) calculated for 0, 5, 10, and 20 nM DA from the zero net flux plots. 
Note these data are not raw data from the experiment but they are the data used to make the 
plots (this is why there are negative values at 0 nM). The x-intercept and slopes obtained from 
linear regressions run on those plots. These plots can be found in Figure 3.4 of Chapter 3 for WT 
and BDNF+/- mice. 
0 nM 5 nM 10 nM 20 nM 
DAext 
(x-intercept) 
Slope Group 
-0.7 0.4 1.4 3.4 2.6 0.28 
WT Control 
-0.7 0.7 2.1 5.0 12.8 0.15 
-1.9 -1.2 -0.4 1.1 12.2 0.30 
-4.8 -2.4 0.0 4.8 7.6 0.43 
-2.4 -1.0 0.4 3.1 8.7 0.28 
-3.3 -1.1 1.0 5.3 10.1 0.48 
-3.7 -2.2 -0.7 2.3 3.2 0.20 
-4.5 -3.0 -1.5 1.5 15.0 0.30 
-5.6 -3.9 -2.3 1.0 11.9 0.32 
WT DID 
-1.4 -0.1 1.1 3.7 5.5 0.26 
-3.8 -2.2 -0.6 2.6 1.6 0.59 
-0.9 2.0 5.0 10.8 7.6 0.25 
-1.9 -0.7 0.6 3.1 9.3 0.16 
-1.5 -0.7 0.1 1.8 16.9 0.33 
-3.2 -0.5 2.3 7.9 13.0 0.23 
BDNF+/- 
Control 
-4.6 -2.7 -0.7 3.1 5.8 0.56 
-1.2 0.6 2.4 3.1 11.9 0.39 
-1.4 0.2 1.9 5.2 3.3 0.36 
-1.5 -0.9 -0.2 1.0 4.3 0.33 
-3.0 -1.8 -0.7 1.6 11.9 0.13 
-1.7 -0.5 0.6 2.8 7.4 0.22 
BDNF+/- DID 
-1.6 0.0 1.6 4.9 5.0 0.32 
-2.2 -1.1 0.0 2.3 9.8 0.23 
-1.2 -0.4 0.4 2.0 7.7 0.16 
-2.5 0.0 2.5 7.6 4.9 0.50 
-4.8 -3.4 -1.9 1.0 16.7 0.29 
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Table A.5 Uncorrected DA levels (in nM) over time used to create the baseline normalized plots 
from the quinpirole infusion experiments in Figure 3.5 of Chapter 3 for WT and BDNF+/- mice. 
20 
min 
40 
min 
60 
min 
80 
min 
100 
min 
120 
min 
140 
min 
160 
min 
180 
min 
200 
min 
220 
min 
240 
min 
Group 
2.0 2.0 2.0 2.8 3.3 3.0 2.4 1.7 1.9 1.4 
 
1.0 
WT 
Control 
1.6 1.4 1.6 1.3 1.2 1.3 1.4 1.3 1.1 1.0 0.7 0.7 
0.5 0.7 0.7 0.7 0.9 
 
0.8 0.5 0.6 0.6 0.4 0.2 
1.2 0.7 0.9 0.9 1.0 1.1 0.8 1.0 0.6 0.7 0.4 0.2 
1.7 1.2 1.5 1.4 1.3 1.4 1.9 1.2 0.9 0.8 0.6 0.4 
1.1 1.1 0.9 1.5 1.4 1.2 
    
0.8 0.7 
4.8 3.3 2.8 2.4 2.2 2.1 2.2 1.8 1.7 1.4 1.2 1.6 
2.6 1.8 2.7 1.2 1.1 1.5 1.0 0.7 0.6 0.5 
 
1.0 
1.3 1.0 1.3 1.8 1.6 1.5 1.4 0.9 0.8 0.2 
 
0.2 
1.4 2.4 1.0 0.9 1.6 1.2 
  
1.0 
 
0.8 0.6 
1.7 1.6 1.8 1.8 2.0 1.8 
   
1.7 1.6 0.7 
1.6 1.5 1.6 1.8 1.5 1.7 1.7 1.7 1.4 1.3 0.9 0.7 
WT DID 
1.2 1.4 1.4 1.7 1.8 1.4 1.3 1.1 1.1 2.2 1.0 0.8 
1.3 1.0 1.1 1.0 1.1 1.1 0.8 0.8 0.6 0.6 0.4 
 
1.5 1.4 1.6 2.4 1.4 0.9 0.7 0.9 0.7 0.6 0.4 0.3 
0.9 1.2 
 
0.8 0.2 
 
0.2 0.7 0.1 -0.1 
  
1.2 0.5 0.5 0.6 1.3 
 
0.9 0.8 0.4 0.4 0.2 0.2 
1.8 1.6 0.9 0.7 0.9 1.0 0.6 0.7 0.6 0.3 0.4 0.3 
2.1 1.5 2.5 1.8 1.6 1.7 2.2 1.7 1.9 1.7 0.9 0.2 
1.0 1.0 0.9 0.5 0.6 0.8 0.9 
 
1.0 0.8 
 
0.7 
1.8 2.0 1.9 1.9 1.8 2.5 1.4 
 
0.9 0.8 0.8 0.7 
BDNF+/- 
Control 
1.9 1.6 1.3 1.5 1.9 1.9 1.7 1.0 1.2 1.0 1.7 1.8 
1.9 0.5 0.9 0.7 1.0 1.0 
 
0.6 0.9 
 
1.0 0.2 
 
0.9 0.9 0.4 0.9 0.8 0.7 0.2 0.2 0.3 0.0 0.1 
2.4 2.3 2.1 2.2 2.2 2.3 2.5 2.1 2.0 1.9 1.8 1.9 
1.6 1.6 2.2 1.3 1.4 0.9 0.8 0.5 0.6 0.4 0.4 0.1 
1.1 1.1 1.3 1.1 1.3 1.1 1.0 0.8 0.6 0.6 0.4 0.5 
BDNF+/- 
DID 
3.8 
 
4.3 5.1 4.9 4.0 4.4 3.6 3.4 3.5 3.1 2.8 
9.2 8.6 9.7 9.3 8.1 8.9 9.1 9.8 7.8 8.5 5.7 6.1 
0.8 0.6 0.8 0.9 1.0 0.9 0.8 0.7 0.6 0.5 0.3 0.5 
2.9 3.0 3.4 3.2 3.1 3.0 3.1 2.5 2.3 1.8 1.3 1.2 
1.9 2.1 2.7 2.6 2.6 2.8 
 
2.1 2.1 1.5 1.1 0.7 
2.1 2.1 2.1 2.3 2.3 3.5 3.5 2.3 1.8 1.8 1.1 1.2 
11.1 14.7 12.2 14.6 11.7 13.1 13.1 12.5 12.7 10.8 8.4 9.7 
1.1 1.1 0.6 1.2 0.8 
 
1.1 0.8 0.7 
 
1.6 1.2 
1.5 1.7 1.1 1.4 1.2 1.1 1.5 0.9 1.2 0.9 0.4 0.7 
1.7 1.4 1.4 1.8 2.1 1.4 0.8 0.8 1.0 1.2 1.3 1.4 
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Table A.6 Daily ethanol consumption (g/kg) for MALE WT and BDNF+/- mice used in the second 
DID study described in Chapter 4. These data were used to create the graphs in Figure 4.1. 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Genotype 
1.47 2.38 2.04 2.54 2.31 2.36 3.59 
WT 
2.78 2.32 1.46 1.86 1.72 2.59 2.73 
2.34 3.06 2.58 1.86 1.89 2.78 4.14 
1.53 2.21 2.21 0.66 1.86 1.78 2.78 
3.27 3.25 1.86 2.08 2.89 3.56 3.23 
3.23 1.08 
 
2.79 2.84 2.52 2.83 
2.26 1.87 1.76 1.86 2.3 4.51 
 
2.2 1.69 3.12 2.07 
 
3.5 2.44 
3.9 2.68 2.82 4.05 5.15 3.06 2.64 
2.73 2.71 2.92 2.71 3.66 2.71 2.83 
3.14 2.64 3.89 1.39 2.02 2.67 3.12 
1.59 1.31 2.5 1.8 2.79 3.25 2.04 
2.23 2.46 2.8 3.45 3.48 4.29 3.13 
0.35 2.03 2.45 1.2 2.3 1.94 3 
BDNF+/- 
2.07 1.81 2.81 3.65 3.12 3.24 4.35 
1.83 1.59 1.73 1.23 1.5 1.7 1.78 
2.15 2.94 1.3 1.57 2.22 2.1 1.8 
0.84 1.21 1.82 2.3 1.23 1.42 1.16 
1.26 1 1.6 1.97 1.69 3.21 2.26 
1.15 1.6 2.31 2.18 1.64 3.48 2.52 
1.32 3.47 3.3 2.76 2.55 2.92 2.14 
2.18 2.57 2.35 2.92 2.83 2.19 2.09 
2.87 2.49 2.05 2.38 2.7 3.51 3.12 
2.83 2.93 3.3 4.97 3.35 2.97 3.26 
1.44 1.91 1.32 1.44 4.07 1.57 2.73 
1.39 2.4 2.81 3.37 2.48 3.48 2.78 
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Table A.7 Daily ethanol consumption (g/kg) for FEMALE WT and BDNF+/- mice used in the second 
DID study described in Chapter 4. These data were used to create the graphs in Figure 4.1. 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Genotype 
4.02 2.68 3.96 4.97 4.44 4.55 2.84 
WT 
3.56 1.73 2.32 2.75 3.02 3.1 1.99 
3.91 3.21 2.56 3.26 2.93 4.07 1.79 
2.63 2.9 2.98 3.37 2.18 2.95 4.09 
3.46 3.96 2.37 4.63 2.08 4.5 3.76 
2.23 3.2 3.46 3.07 2.75 2.98 3.35 
2.55 1.78 2.33 4.28 3.19 4.87 4.77 
3.75 3.79 4.42 3.52 4.44 3.71 4.36 
3.48 3.04 4.09 3.43 3.2 2.42 3.53 
4.3 2.25 4.08 2.68 2.37 3.36 4.18 
   
2.68 3.15 3.43 3.51 
BDNF+/- 
2.92 1.59 3.28 3.12 3.72 3.06 4.28 
3.77 
  
3.13 4.27 2.89 3.93 
1.72 2.11 2.2 2.68 3.69 1.7 
 
2.15 3.61 3.52 3.11 2.73 2.7 4.1 
3.58 2.3 3 2.79 2.89 2.56 2.64 
1.18 2.64 2.57 2.62 2.86 2.3 1.93 
1.87 3.53 3.75 3.14 3.22 3.64 2.69 
4.04 2.83 1.83 3.77 2.33 2.73 3.85 
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Table A.8 BDNF levels (ng/mg ww) used to make the raw data plots and the normalized data 
plots in Figure 4.2 of Chapter 4. 
Male Female 
BDNF  
(ng/mL ww) 
Genotype Group 
BDNF  
(ng/mL ww) 
Genotype Group 
20.6 
WT Control 
42.8 
WT control 
30.37 15.46 
24.3 11.2 
56.6 11.32 
15.15  
29.76 
WT 30 min 
24.3 
WT 30 min 13.64 18.03 
9.44 7.87 
12.02 
WT 24 hour 
19.38 
WT 24 hour 
8.8 8.82 
30.06  
17.57  
8.95  
11.63  
7.29 
BDNF+/- Control 
6.92 
BDNF+/- Control 
7.41 9.04 
12.33 9.06 
12.89 8.97 
6.45 10.86 
4.76 
 
4.77 
 
4.72 
 
8.1 
BDNF+/- 30 min 
4.73 
BDNF+/- 30 min 
6.49 3.9 
4.8 5.47 
5.6 
 
5.44 
BDNF+/- 24 hour 
0.06 
BDNF+/- 24 hour 
7.28 1.31 
11.17  
8.86 
 
3.99 
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Figure A.1 Inversion of the film from the male blot for the phosphorylated receptor (p-FL-TrkB 
and p-T-TrkB). From left to right the blue boxes indicate WT: control, 30 min and 24 hours; the 
green boxes indicate BDNF+/-: control, 30 min, and 24 hour. Figures 4.3 and 4.4 in Chapter 4. 
 
 
Figure A.2 Inversion of the film from the female blot for the phosphorylated receptor (p-FL-TrkB 
and p-T-TrkB). From left to right the blue boxes indicate WT: control, 30 min and 24 hours; the 
green boxes indicate BDNF+/-: control, 30 min, and 24 hour. Figures 4.5 and 4.6 in Chapter 4. 
 
 
Figure A.3 Image of blot for the total TrkB levels (FL-TrkB and T-TrkB) in male mice. From left to 
right the blue boxes indicate WT: control, 30 min and 24 hours; the green boxes indicate BDNF+/-
: control, 30 min, and 24 hour. Figures 4.3 and 4.4 in Chapter 4. 
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Figure A.4 Image of blot for the total TrkB levels (FL-TrkB and T-TrkB) in female mice. From left 
to right the blue boxes indicate WT: control, 30 min and 24 hours; the green boxes indicate 
BDNF+/-: control, 30 min, and 24 hour. Figures 4.5 and 4.6 in Chapter 4. 
 
Figure A.5 Image of blot for the actin loading control for male mice. From left to right the blue 
boxes indicate WT: control, 30 min and 24 hours; the green boxes indicate BDNF+/-: control, 30 
min, and 24 hour. Figures 4.3 and 4.4 in Chapter 4. 
 
 
Figure A.6 Image of blot for the actin loading control for female mice. From left to right the blue 
boxes indicate WT: control, 30 min and 24 hours; the green boxes indicate BDNF+/-: control, 30 
min, and 24 hour. Figures 4.5 and 4.6 in Chapter 4. 
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Table A.9 Values obtained from the western blot for male mice, used to create the histograms in 
figures 4.3 and 4.4 in Chapter 4. 
p-FL-TrkB p-T-TrkB FL-TrkB T-TrkB Actin Genotype Group 
53.973 49.877 38.254 59.905 45.988 
WT Control 44.151 26.624 31.254 60.622 42.66 
50.684 15.183 21.223 74.693 40.561 
24.308 11.253 118.493 160.113 63.774 
WT 30 min 48.368 18.448 35.43 135.03 47.107 
26.279 17.975 66.9 129.935 56.035 
59.716 47.298 52.708 125.817 61.246 
WT 24 hour 62.686 37.9 56.408 112.816 55.807 
60.826 38.219 67.661 103.899 47.216 
46.1 13.228 40.492 72.645 42.457 
BDNF+/- Control 55.159 24.537 47.708 61.627 43.533 
43.965 33.637 74.123 63.823 46.985 
6.937 -0.505 57.292 62.462 10.347 
BDNF+/- 30 min 39.502 57.64 71.092 55.763 31.538 
38.134 43.846 44.516 52.758 41.456 
51.141 53.03 38.408 73.012 43.826 
BDNF+/- 24 hour 35.104 13.259 25.584 107.598 26.081 
40.927 36.868 73.061 116.213 52.419 
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Table A.10 Values obtained from the western blot for female mice, used to create the 
histograms in figures 4.3 and 4.4 in Chapter 4. 
p-FL-TrkB p-T-TrkB FL-TrkB T-TrkB Actin Genotype Group 
68.616 70.563 21.222 50.651 53.339 
WT Control 
51.161 59.742 19.113 46.426 41.813 
80.565 82.439 26.097 72.421 57.091 
75.932 83.139 32.341 79.057 55.061 
64.392 73.042 43.012 98.313 53.834 
WT 30 min 70.427 87.284 41.164 79.133 52.576 
56.601 72.629 46.898 84.584 64.622 
84.174 89.27 56.142 97.349 56.436 
WT 24 hour 45.466 74.036 40.097 85.595 46.762 
79.397 89.869 38.92 73.989 58.344 
63.891 70.878 37.841 49.908 58.101 
BDNF+/- Control 71.173 75.912 51.881 52.989 62.992 
65.426 62.995 40.977 86.815 61.213 
38.019 36.949 60.113 86.862 46.661 
BDNF+/- 30 min 
72.667 74.918 95.443 137.246 78.224 
49.622 57.216 68.932 119.452 71.494 
63.344 47.591 49.807 120.702 67.268 
BDNF+/- 24 hour 9.874 1.719 32.954 127.046 46.254 
53.957 30.545 36.443 122.81 56.117 
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Table A.11 DA levels (in nM) calculated for 0, 2.5, 5, and 10 nM DA from the zero net flux plots. 
Note these data are not raw data from the experiment but they are the data used to make the 
plots (this is why there are negative values at 0 nM). The x-intercept and slopes obtained from 
linear regressions run on those plots. These plots can be found in Figure 5.2 of Chapter 5 for WT 
and DKO mice. 
0 nM 2.5 nM 5 nM 10 nM 
DAext 
(x-intercept) 
Slope Genotype 
-0.33 0.17 0.68 1.69 1.64 0.17 
WT 
-0.57 -0.13 0.30 1.17 3.26 0.13 
-1.36 -0.10 1.15 3.67 2.71 0.50 
-0.50 0.25 0.99 2.48 1.66 0.30 
-0.90 -0.05 0.80 2.51 2.65 0.34 
-1.02 -0.47 0.07 1.16 4.68 0.22 
-1.99 -1.18 -0.36 1.27 6.12 0.33 
-1.05 0.07 1.20 3.46 2.33 0.45 
DKO 
-0.62 0.08 0.79 2.20 2.21 0.28 
-0.46 0.14 0.75 1.97 1.91 0.24 
-0.96 -0.30 0.36 1.68 3.65 0.26 
-1.12 -0.01 1.09 3.31 2.53 0.44 
-0.46 0.30 1.06 2.58 1.52 0.30 
-0.34 -0.09 0.17 0.67 3.35 0.10 
-2.20 -0.26 -0.31 1.58 5.24 0.34 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
 
Table A.12 Uncorrected DA levels (in nM) over time used to create the baseline normalized plots 
from the ethanol challenge experiments in Figure 5.3 of Chapter 5 for WT and DKO mice. For the 
1 g/kg dose a 180 minute fraction was not collected. 
20 
min 
40 
min 
60 
min 
80 
min 
100 
min 
120 
min 
140 
min 
160 
min 
180 
min 
Genotype Dose 
0.30 0.39 0.25 0.16 0.13 0.20 
   
WT 
1 
g/kg 
 
0.35 0.28 0.34 0.32 0.27 0.16 
  
WT 
0.60 0.45 0.37 0.27 0.41 0.16 0.31 0.27 
 
WT 
1.36 1.47 1.46 2.06 2.91 1.38 0.94 1.36 
 
WT 
2.08 1.50 1.44 1.77 1.45 1.14 1.40 1.18 
 
WT 
0.44 0.46 0.30 0.38 0.30 0.14 0.27 0.51 
 
WT 
0.41 0.55 0.34 0.47 0.19 0.46 0.43 0.37 
 
WT 
0.51 0.32 0.44 0.47 0.46 
 
0.48 0.47 
 
DKO 
0.23 0.45 0.34 0.41 0.20 0.32 0.34 0.30 
 
DKO 
1.26 1.82 
 
0.95 1.20 1.30 1.05 0.98 
 
DKO 
1.60 1.76 
 
1.24 1.29 0.88 1.01 1.08 
 
DKO 
0.28 0.18 0.23 0.25 0.27 0.24 0.13 0.24 
 
DKO 
0.77 0.66 0.76 0.83 0.92 0.81 0.59 0.43 0.52 WT 
2 
g/kg 
0.86 1.01 0.67 0.70 2.14 1.63 1.30 1.06 1.43 WT 
0.35 0.24 0.14 0.29 0.16 
 
0.19 0.19 
 
WT 
 
0.49 0.47 0.53 0.58 
  
0.38 
 
WT 
0.13 0.10 
 
0.12 0.16 0.06 0.17 
  
WT 
0.12 0.08 0.03 0.20 0.21 0.18 0.21 0.10 0.07 WT 
0.16 0.19 0.26 0.32 0.37 0.27 0.30 
  
WT 
0.76 0.74 0.88 2.09 0.46 0.72 0.53 1.27 0.63 WT 
2.13 1.55 1.44 2.01 1.85 2.40 2.04 1.60 2.07 DKO 
0.52 0.51 0.66 0.49 0.45 0.59 0.48 0.47 0.51 DKO 
 
0.58 0.48 0.56 0.59 0.46 
 
0.56 0.43 DKO 
0.44 0.34 0.35 0.42 0.38 0.31 0.38 0.37 0.59 DKO 
0.60 0.40 0.36 0.40 0.35 0.38 0.37 0.38 0.39 DKO 
0.56 0.63 0.54 0.55 0.62 0.46 0.39 0.41 0.58 DKO 
 
1.72 1.00 0.82 
  
0.38 0.35 0.23 DKO 
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Table A.13 Uncorrected DA levels (in nM) over time used to create the baseline normalized plots 
from the 5 mg/kg METH challenge experiments in Figure 5.4 of Chapter 5 for WT and DKO mice. 
Time WT 
20 min 
  
0.07 0.20 0.53 1.52 
 
1.23 
 
40 min 0.73 0.27 
 
0.16 
 
1.28 2.63 1.48 0.60 
60 min 0.52 0.34 0.19 0.20 0.74 1.51 2.51 1.13 0.48 
80 min 5.55 2.22 0.63 1.55 5.11 6.30 6.88 2.99 26.33 
100 min 20.55 3.11 13.27 2.78 14.16 14.66 17.64 
 
50.11 
120 min 19.22 2.94 
 
4.92 11.43 12.01 14.43 3.67 19.73 
140 min 16.22 3.00 7.47 4.28 9.08 9.39 
 
4.00 20.57 
160 min 10.68 2.94 3.57 3.80 6.24 8.06 
 
1.31 14.25 
180 min 8.08 2.38 2.27 1.08 
 
5.89 5.31 2.22 5.25 
200 min 7.60 1.56 1.94 0.89 
 
4.47 3.81 2.05 2.84 
220 min 5.18 1.19 1.30 0.84 1.98 3.55 2.79 1.87 1.69 
240 min 3.80 1.10 0.87 0.64 1.31 2.46 2.77 1.81 1.42 
260 min 3.00 0.61 0.88 0.56 1.27 2.07 2.34 1.31 1.57 
280 min 2.47 0.46 0.74 0.64 0.75 2.38 
 
1.00 0.53 
300 min 
 
0.36 0.42 0.25 
 
1.62 0.91 
 
0.64 
Time DKO 
20 min 0.46 0.44 1.72 0.62 0.31 1.16 0.29 0.82 
 
40 min 0.36 0.45 1.07 0.50 0.40 1.00 0.10 0.74 
 
60 min 0.40 0.46 1.15 0.70 0.32 
 
0.98 0.74 
 
80 min 2.71 0.89 14.65 11.39 5.78 6.12 1.99 12.68 
 
100 min 14.46 4.78 34.81 33.66 8.57 20.42 5.18 44.33 
 
120 min 7.56 
 
25.12 31.94 7.19 18.68 5.81 33.55 
 
140 min 7.65 4.31 15.17 
 
6.15 14.63 2.64 19.54 
 
160 min 4.46 2.17 14.88 15.76 4.12 10.26 
 
15.25 
 
180 min 3.24 1.24 9.92 9.30 3.25 7.03 
 
8.41 
 
200 min 2.10 
 
8.41 7.71 2.63 5.42 0.93 6.45 
 
220 min 1.61 0.93 7.85 6.70 2.37 
 
0.57 5.70 
 
240 min 1.34 1.16 8.84 6.58 2.37 3.42 0.31 4.56 
 
260 min 
   
4.79 2.70 3.60 0.48 4.57 
 
280 min 
   
3.56 1.96 1.94 0.30 4.39 
 
300 min 
   
2.82 1.44 2.94 0.42 3.81 
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Table A.14 Drinking data in (g/kg) for a pilot study where one WT and BDNF+/- mouse each went 
through 7 days of DID followed by a 3-day cessation and reinstatement. This data was used to 
make Figure 6.3 in Chapter 6. 
Day WT BDNF+/- 
1 2.63 2.13 
2 3.10 3.38 
3 2.13 2.58 
4 2.69 2.06 
5 2.78 2.20 
6 2.99 1.97 
7 3.76 3.25 
8 X X 
9 X X 
10 X X 
11 1.56 3.87 
12 1.95 3.04 
13 2.12 2.79 
14 2.83 2.62 
 
Table A.15 Baseline corrected DA levels (in %, ([DA]/[average DA])*100) over time used to 
create the plots from the 2 g/kg ethanol challenge experiments after 1 day of DID in WT and 
BDNF+/- mice. This data was used in Figure 6.4 of Chapter 6. 
20 
min 
40 
min 
60 
min 
80 
min 
100 
min 
120 
min 
140 
min 
160 
min 
180 
min 
Genotype 
108.6 110.1 81.3 166.0 128.4 160.7 117.0 107.1 91.7 
WT 
98.0 108.3 93.7 95.7 122.9 129.3 101.2 96.5 106.1 
97.5 112.0 90.5 
 
86.8 83.3 76.4 97.2 87.9 
BDNF+/- 
 
110.9 107.7 81.4 69.8 80.6 73.0 57.7 59.7 
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 Brain-derived neurotrophic factor (BDNF) is an important neuromodulator that has 
implicated in regard to several neurological disorders, including alcohol addiction. BDNF is also 
an important modulator of dopamine (DA), a neurotransmitter that is heavily implicated in 
addiction with one of the DA rich brain regions being referred to as the reward center of the 
brain.  One of the focuses in alcohol dependence research includes determining risk factors that 
make an individual more susceptible to becoming dependent. BDNF has been of interest as a 
risk factor due to its involvement in ethanol consumption and addiction evidenced in a vast 
number of studies using both human and animal models. The goal of this study was primarily to 
understand how low endogenous BDNF levels could lead a person to be more susceptible to 
alcohol dependence/ addiction. This was coupled with the goal of understanding ethanol’s 
alterations on the striatal DA system. Using two different mouse models and both voluntary 
ethanol consumption along with acute exposure to ethanol via systemic injection several striatal 
alterations were observed. Seven days of voluntary binge-like ethanol consumption produce a 
tolerance to ethanol stimulation of DA release, which could be mediated by alterations in 
adenylyl cyclase (AC) isoforms. BDNF and its receptor (tyrosine kinase B, TrkB) are reduced in 
WT mice, but not in BDNF-deficient mice following DID. The alterations observed with BDNF and 
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TrkB could have important implications for the continued used of the DID model. Finally using 
double-knockout animals that lack AC1 and AC8 it was shown that these isoforms are necessary 
for ethanol-stimulation of DA. Together these findings show how quickly neuroadaptations can 
occur following ethanol exposure and provide several avenues for future investigations. 
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